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ABSTRACT 
Staphylococcus aureus is an important pathogen causing chronic and invasive 
disease worldwide. This bacterium is a leading cause of community and hospital acquired 
infections in humans, and is also known to infect wild and domestic animals. Bovine 
mastitis, or inflammation of the udder, is one of the most economically relevant diseases 
of the dairy industry, with a high incidence worldwide. S. aureus is a major etiological 
agent causing this disease. S. aureus mastitis is highly contagious and difficult or 
impossible to treat. Management practices at dairy farms, that include good sanitation and 
antibiotic use, have been partially successful in reducing the occurrence of this disease, 
however, a complete prevention or elimination is still to be achieved. Despite efforts over 
more than two decades, an effective vaccine for S. aureus mastitis, that can protect 
against heterologous strains of this bacterium, is not yet available. These efforts however, 
have improved our understanding of the pathogenicity, virulence factor expression and 
immune responses to this bacterium. Studies have indicated that there is significant 
intraspecies variability, and an effective vaccine against S. aureus will require the 
incorporation of multiple conserved and relevant antigens. Additionally, the route of 
vaccine administration and use of adjuvants to aid in antigen delivery and enhancement 
of immune responses will also be critical.  
S. aureus contains a broad array of virulence factors required for colonization and 
disease, including: adhesins, toxins, a polysaccharide capsule, enzymes and immune 
evasion molecules, that are required for adhesion, invasion and colonization. Some 
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virulence factors are highly conserved and centrally important for bacterial survival and 
sustenance, making them good vaccine targets. The iron-regulated surface determinant A 
(IsdA) and clumping factor A (ClfA) are two such conserved S. aureus extracellular-
matrix adhesins that are promising vaccine antigens. However, an effective S. aureus 
vaccine for the prevention or reduction of mastitis will need to induce mucosal and 
systemic, as well as cellular and humoral, immune responses to these antigens. Bacterial 
enterotoxins are well characterized vaccine adjuvants that act by enhancing the mucosal 
delivery of antigens and promoting both systemic and mucosal humoral responses. 
Cholera toxin (CT), from Vibrio cholerae is a gold-standard vaccine adjuvant that can 
promote both humoral and cellular immune responses to co-administered antigens when 
delivered to mucosal surfaces. 
The work presented here is based upon the overarching hypothesis that a mucosal, 
enterotoxin-based vaccine containing multiple relevant antigens will protect cows 
against S. aureus mastitis. To construct this vaccine, three immediate aims were 
developed. First, to ensure the incorporation of relevant antigens, the variability, genetic 
conservation and immunogenicity of the IsdA protein during bovine infection was 
determined. Second, a cholera toxin adjuvant based vaccine containing IsdA and a second 
antigen, ClfA (IsdA-CTA2/B +ClfA-CTA2/B) was used to vaccinate cows to determine 
immunogenicity. Lastly, a new immunoproteomics approach was used to identify 
immunogenic antigens for future incorporation into a multivalent vaccine. The results 
from these studies, as presented in chapters 2-4, indicate that: 1) the IsdA adhesin is 
expressed and conserved in bovine strains of S. aureus, 2) IsdA-CTA2/B + ClfA-CTA2/B 
can stimulate significant immune responses in vaccinated animals after intranasal 
 x 
 
administration and 3) immunoproteomics using milk antibodies can be used to identify 
new potential S. aureus vaccine antigens. The studies presented here will contribute to 
the advancement and understanding of staphylococcal vaccines in general, and 
specifically to those that will prevent bovine mastitis. 
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expression are shown after growth of NC in A) 5% skim milk (SKM) 
compared to Luria broth (LB), B) low iron media (LIM) compared to LB 
and C) SKM plus FeSO4 compared to SKM alone, after 24 hours at 37C. 
D) Growth curve in CFU/mL of NC growth LB (green), SKM (red) and 
LIM (blue). Significance using the Tukey-Kramer pairwise comparison, 
p ≤ 0.05(*), p ≤ 0.01(**), p ≤ 0.001 (***) or p ≤ 0.0001 (****) between 
the expression of genes is shown. .......................................................... 154 
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CHAPTER ONE: CHARACTERIZATION OF STAPHYLOCOCCUS AUREUS 
INFECTION AND ITS PREVENTION BY VACCINE 
 
Background and Introduction 
Staphylococcus Aureus “the super bug” 
Staphylococcus aureus (S. aureus) is a gram positive pathogen that is known to 
colonize almost 30% of the human population, according to the CDC [1]. S. aureus 
causes a wide range of clinical disease and life-threatening conditions like pneumonia, 
endocarditis, toxic shock syndrome and sepsis [2]. This pathogen has long been 
considered a high risk to public health; causing both hospital acquired and community 
infections in humans. S. aureus is the fourth most common hospital-acquired pathogen 
and the second most common pathogen isolated from surgical sites, causing 9% of 
nosocomial infections in United States alone [3,4]. Antibiotic therapy to treat this 
pathogen is either ineffective or challenging due to the prominence of antibiotic resistant 
strains like MRSA (methicillin-resistant S. aureus) and VRSA (vancomycin-resistant S. 
aureus), which are resistant to almost all common use antibiotics [5]. It is estimated that 
more than 2 million humans are sickened every year with antibiotic resistant strains of S. 
aureus [6]. In 2011, the CDC identified 80,461 cases of severe MRSA infection, which 
resulted in 11,285 deaths [7]. 
In addition to being an important pathogen for humans, S. aureus colonizes and 
infects almost all animal species. S. aureus has been reported to cause severe pathologies 
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in pets, wildlife and livestock [8,9]. Importantly, S. aureus is known to cause one of the 
most prevalent diseases of the dairy industry, called bovine mastitis. Bovine mastitis is 
common in all countries worldwide, and is reported to occur in anywhere from 5% to 
70% of cows, depending upon herd and location, and in up to 90% of herds [10]. 
Multiple pathogens can cause bovine mastitis; however, S. aureus caused mastitic 
infections are persistent, contagious, and difficult to treat, with low cure rates [11]. S. 
aureus mastitis often becomes a chronic and clinical or subclinical inflammatory disease 
of the cow udder caused by intra-mammary infection [12]. This is one of most 
economically relevant diseases of the dairy industry, causing large economic losses every 
year, mainly due to reduced milk yield and quality. While it is difficult to estimate the 
losses caused by S. aureus alone, the economic losses caused by bovine mastitis in 
general are estimated to be approximately 1.5 billion/year in US, or $100-200/cow [13–
15]. Improved health management practices at dairy farms have decreased levels of S. 
aureus infection and disease, however eradication is currently far from achieved.  
Attempts to design a vaccine for S. aureus have occurred over decades, however, 
an effective vaccine to prevent disease and transmission is still not available for humans 
or bovines. Current S. aureus vaccines are either inconsistent or not protective. This is 
likely due to the significant intra-species variability of S. aureus and its multitude of 
potent virulence factors. The pathogenesis of S. aureus is mediated by this array of 
factors, that includes; cell wall proteins, secreted factors, immune evasion molecules and 
toxins. These multifunctional proteins and molecules are very important for S. aureus 
proliferation and survival inside the host. Many virulence factors play a critical role in 
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adhesion, invasion and pathogenesis and hence their presence is highly conserved in 
different strains and serotypes. 
A vaccine strategy that incorporates conserved virulence factors or cell wall 
anchored proteins as antigens will more effectively stimulate cross-protective immune 
responses and aid in the eradication of S. aureus disease and colonization. The following 
studies focused on developing a cholera toxin adjuvant based vaccine for S. aureus 
caused bovine mastitis. Additionally, the identification and characterization of various 
virulence factors involved in the infective stage of disease pathogenesis for use as 
vaccine targets is described in this work. 
Virulence and Pathogenicity of S. aureus 
Colonization of S. aureus is a risk factor for invasive disease. Skin and mucosal 
surfaces, like the nose, throat, vaginal wall, and gastrointestinal (G.I.) tract, are the 
common sites of  S. aureus colonization [16]. The squamous epithelium of anterior nares 
is transiently colonized in 60%, and permanently in 20%, of the population [17]. One of 
the major concerns about nasal colonization is the potential dissemination of the 
bacterium to other parts of the body. It has been reported that when nasally colonized 
individuals were topically treated for their colonization in the nose, the infection rate of S. 
aureus in these individuals to other parts of body was significantly reduced [17]. 
The S. aureus surface and secreted proteins contribute to an extraordinary arsenal 
of virulence factors, promoting  survival in extreme conditions within host [10]. These 
proteins, that promote colonization to  host extracellular matrix (ECM), growth in serum 
or tissue, and avoidance of the immune system are important as vaccine antigenic targets 
[18]. The majority of these are either secreted from the bacterial cell or anchored to the 
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cell wall through sortase action. The expression of these proteins is carefully controlled 
by S. aureus to be expressed in response to the challenges encountered in the host for 
colonization and survival [19]. Expression is controlled by growth phases, like stationary 
or exponential growth, and nutritional conditions, like the limited availability of iron and 
other nutrients [20]. Thus the surface of the bacterium plays a critical role in interactions 
with  the environment and the host [21]. It has been reported that S. aureus can express 
up to 24 different cell wall anchored proteins at a given time [22].  
Although colonization of S. aureus is associated with increased risk for infection; 
the carriers of S. aureus usually exhibit less severe symptoms of disease than typically 
seen in non-carriers [17]. This can be explained by the presence of a higher level of anti-
staphylococcal antibodies in the S. aureus carriers as compared to non-carriers [23]. 
Carriers have been found to predominantly induce antibodies to adhesive and ECM-
binding proteins [24]. Adhesion to the host is a pivotal step in the pathogenesis of S. 
aureus, and is a prerequisite for colonization and infection of the host. The wide variety 
of proteins and factors that aid in this process are called adhesins. Bacterial adhesins 
mediate attachment  to ECM, epithelial cells, plasma proteins, endothelial cells and other 
microorganisms [25]. Adhesins can be bound on the surface or can be secreted. The S. 
aureus Microbial Surface Components Recognizing Adhesive Matrix Molecules 
(MSCRAMMs) are the most prevalent group of surface associated adhesive proteins. 
Whereas, secreted S. aureus adhesins are commonly referred to as secretable repertoire 
adhesive molecules (SERAMs) [26]. MSCRAMMs and SERAMs  bind to abundant 
ECM molecules like fibronectin (FN), fibrinogen (FG), vitronectin, hemin, bone 
sialoprotein, transferrin and collagen [27–34]. Adhesion to mucosal surfaces and 
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resistance to innate immunity at this surface is key to pathogenesis, and S. aureus is a 
common skin and nasal commensal. Surprisingly, animal S. aureus strains possess very 
similar adhesive and immune evasion proteins to human strains, although the targets are 
substantially different. Table 1-1 shows S. aureus adhesins and surface proteins that have 
been prominently important in causing infection, invasion and colonization in both the 
animal and human host [35]. 
Table 1-1 S. aureus virulence factors involved in adhesion to the host. 
Name  Gene  Function 
Fibronectin binding proteins A, B 
 
fnbpA, B Adhesins to fibronectin (FN), fibrinogen (FG) 
and elastin 
Collagen-binding adhesin 
 
Iron-regulated surface protein A (IsdA) 
 
 
Iron-regulated surface protein B (IsdB) 
 
Iron-regulated surface protein C (IsdC) 
Iron-regulated surface protein H (IsdH) 
Serin-aspartate repeat proteins C, D and E 
Bone sialoprotein-binding protein 
Staphylococcal protein A 
 
Extracellular adherence protein  
 
 
Alpha toxin 
Transglucosylase IsaA 
ESAT-6 secretion system extracellular 
protein A 
cnA 
 
isdA 
 
 
isdB 
 
isdC 
isdH 
sdrs 
bpB  
SpA 
 
eap/map 
 
 
hlA 
isaA 
esxA 
Adhesins to collagen (I and IV) 
 
Iron sequestration, cellular hydrophobicity, 
resistance to lactoferrin, binds to FN, FG, 
haem, hemin, transferrin and fetuin. 
Binds to haemoglobin and haem, Iron 
sequestration 
Binds hemin, haem transport to cytoplasm 
Binds hepta-haemoglobin, iron sequestration 
Adhesins 
Binds bone sialoprotein and FG 
Binds Fc domain of Ig, complement factor C3, 
Causes degradation of immunoglobulins 
MHC-II analog, binds to FN, FG, vitronectin 
and collagen, adhesion to host cells, biofilm 
formation 
Pore forming toxin 
Lytic transglucosylase of S. aureus  
Involved in abscess formation, virulence factor 
and pathogenesis 
Fe (Ferrous iron transport protein B) 
Staphylococcal super antigen-like 5, 
11,1 and 7 
Capsular polysaccharides  
feoB 
Ssl 5, 
11,10,7 
CPSs 
ferrous iron transmembrane transporter activity 
Neutrophil migration, binds to chemokine 
receptor, Fc region of IgA. 
Alters C3 (CPS5 and 8) or C3b deposition 
Clumping factor, A 
 
Clumping factor, B 
 
clfA 
 
clfB 
Adhesion to FG, binds complement factor I 
Binds to FG and cytokeratin, skin and nares 
colonization 
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Cell wall anchored S. aureus proteins possess secretory or sec signal sequence on 
the N-terminus and sortase or sorting signal at C-terminus. The sorting signal is 
comprised of the LPXTG (Leu-Pro-X-Thr-Gly; X= any amino acid) motif [36]. Cell wall 
anchored MSCRAMMs can perform multiple functions, are structurally similar and have 
a common mechanism of ligand binding [37]. MSCRAMMs are often the first proteins to 
interact with the host, and hence support colonization and immune evasion. S. aureus 
possess much genetic plasticity and is involved in horizontal gene transfer, thus  different 
proteins often perform similar functions, resulting in significant redundancy [38]. This 
redundancy is an advantageous adaptation for S. aureus to sustain growth in different 
host environments. However, redundancy is a huge disadvantage in determining 
functional and physiological roles of these adhesins by mutational study designs. 
In addition to adhesion, iron uptake is essential for growth and survival of S. 
aureus inside the host. Due to its limited bioavailability, S. aureus has evolved multiple 
iron acquisition systems to survive [39]. Iron in animal tissues and serum is sequestered 
in the form of transferrin, leaving very low amounts of free iron, approximately to the 
order of 10-24 M, which is well below the levels required by bacteria to sustain life [40]. 
The acquisition of iron in S. aureus is regulated by the Ferric Uptake Regulator (FUR). 
The Fur regulator can sense the bioavailability of iron, and act as a repressor to bind and 
inhibit the expression of target genes when iron is abundant. However, when iron is 
limiting, Fur repression is lifted [41]. Iron regulated surface adhesins (Isd) contain Fur 
box sequences upstream of their operon [42]. The Fur regulator is highly conserved in S. 
aureus, as well as other bacterial pathogens, and essential for iron sequestration [43]. 
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The Isd proteins were first identified in 2002, by Mazmanian et al [44]. The series 
of Isd surface adhesins and siderophores work in a coordinated manner to transfer haem 
from haemoglobin across the membrane and to the cytoplasm. Isd adhesins are known to 
have low levels of interstrain variability, potentially due to their critical role in S. aureus 
pathogenesis [22]. Four main Isd proteins, out of a total of nine, are anchored to the cell 
wall by the cleavage enzymes, sortase A or sortase B. IsdA, IsdB, and IsdH contain 
sortase A recognition sequences, which contain a LPXTG motif, and are covalently 
attached to the cell wall [45]. IsdC however, has a distinct recognition sequence, 
NPQTN, and is anchored to the cell wall by sortase B [30]. All the other Isd proteins 
(DEF) are membrane localized in the ABC transporter system [46]. Multiple studies have 
proposed the mechanism of iron acquisition by the Isd proteins using haem receptors 
[33,34,44,47,48]. Conserved, 125 amino acid long, haem-binding motifs are present in all 
Isd proteins that are  putative iron transporters [49]. IsdA, IsdB, IsdH, and IsdC contain 
these NEAr Iron Transporter (NEAT) motifs. IsdA and IsdC has one NEAT motif, IsdB 
has two, and IsdH has three. Iron acquisition through the Isd system starts with the 
binding of haemoglobin, myoglobin or hepta-haemoglobin by IsdB and IsdH (Figure 1-
1). IsdB and IsdH can then extract haem and transfer bound haem to either IsdA or IsdE 
directly. The transfer of haem however from IsdA is unidirectional through the cell wall 
only to IsdC and then IsdE. Haem is further transferred to the bacterial cytoplasm from 
IsdE to IsdF, where an ABC permease transfers the molecule across the membrane using 
the ATP hydrolyzing ability of IsdD. Haem is degraded to iron by the Fur regulated 
cytoplasmic proteins; IsdG and IsdI. Studies reveal that IsdC is essential for this process 
and there can be no transfer of haem between IsdA to IsdE [48]. 
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Figure 1-1. Mechanism of iron sequestration by S. aureus. Depiction of the 
mechanism of Isd-mediated iron sequestration by S. aureus. The first two NEAT 
domains of IsdH and first NEAT domain of IsdB bind to hepta-haemoglobin and 
meth-haemoglobin, which is then transferred to IsdA, and passed in the cell 
membrane via IsdC. The bound haem is then moved through the membrane by 
IsdDEF, which is then degraded into free iron by IsdG and IsdI. The NEAT domains 
of the Isd proteins shown in figure were extracted from the PDB website using the 
accession numbers 2H3K, 2MOQ, 2ITE, 2O6P, 2ZDO, 2ZDP [50–53]. 
In addition to its role in iron-acquisition, IsdA is one of the most well-
characterized  ECM binding adhesins [54]. IsdA has been shown to bind to FN, FG, 
transferrin and haem, with higher binding affinity to FN then FG [54]. The affinity of FG 
binding to IsdA is in micromolar dissociation constant (Kd) ranges, and 20-fold higher 
than that of Clumping factor A (ClfA) [34]. It is known that IsdA can bind to iron bound 
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ligands, however, it cannot bind to haemoglobin and hence it is not required for iron 
acquisition in the host [29]. IsdA is also reported to promote skin colonization by 
increasing the hydrophilicity or negative charge on S. aureus making it less susceptible to 
killing by the skin’s natural antimicrobials [54]. Human skin is an effective barrier to 
infection, with epithelial cells and cross-linked keratin, and containing antimicrobial 
peptides and fatty acids on the surface for defense. In particular, cis-6-hexadecanoic acid 
in the sebum of human skin has antimicrobial activity. However, IsdA confers protection 
to S. aureus against fatty acid, and enables S. aureus to colonize the skin, by increasing 
hydrophobicity, and reducing hydrophobic interactions. Reports suggest that IsdA 
mutants are more susceptible to killing by human sebum, and supplementation with IsdA 
can fully restore the resistance phenotype [54]. 
Other S. aureus adhesins have also been well studied. The collagen binding 
protein Cna, the FN binding FnBP, and the FG binding ClfA, are cell wall anchored 
MSCRAMMs that initiate bacterial adhesion to ECM during intravascular infection. 
FnBP contains two very similar groups of proteins called FnbpA and FnbpB encoded by 
closely linked genes. In vitro studies suggest the importance of FnBP in adherence of S. 
aureus during infection, however, there is contrasting data for the involvement of this 
adhesion in endocarditis in rat models [55,56]. ClfA and ClfB are also two closely linked, 
but distinct adhesins. ClfA is an MSCRAMM from S. aureus that binds to the C-terminus 
of the FG γ-chain [57]. ClfA is also a well-studied virulence factor responsible for 
platelet aggregation and clumping of S. aureus in blood plasma and ClfA is a key factor 
in a mouse model of septic arthritis and rabbit/rat models of infective endocarditis 
[58]. ClfB can also bind to FG and is known to have a prominent role colonization of the 
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anterior nares by binding to cytokeratin [29]. The collagen binding Cna adhesin has been 
shown to promote adherence of S. aureus to cartilage [59]. The expression of Cna in an S. 
aureus cna- mutant  increases its virulence [59]. Surface protein A (SpA) can bind to IgG 
and IgM antibodies, can inhibit opsonophagocytosis and inflammation, and is also a B 
cell super antigen [57]. FN-binding proteins from S. aureus are of particular importance, 
as they have the ability to bind to various types of cells in the host and can act as 
invasins, forming a bridge between S. aureus and integrin on the surface of non-
professional phagocytes [60].  
Other virulence factors of S. aureus include immune evasion molecules such as: 
enterotoxins, inhibitory factors and exopolysaccharides (capsule) [61]. Capsular 
serotypes 5 and 8 have been reported to be present in up to 70% of human and ruminant 
mastitis isolates, however expression is known to be variable [2]. The ability of the 
bacterium to colonize in tissues and disseminate throughout the host is reliant on this 
differential expression. Capsule production in S. aureus, as well as the expression of 
many other secreted and cell-associated virulence factors are under the control of the 
global regulator, accessory gene regulator (agr) [36] Given the importance of these 
virulence factors from S. aureus and their conserved nature, there have been many 
attempts to design vaccines based upon them. S. aureus adhesins that have been the most 
frequently studied as vaccine candidates for humans and animals are described below. 
S. aureus Vaccine Antigens and Vaccines 
IsdA 
As described above, IsdA is an iron-sequestering cell wall anchored protein and 
an important ECM adhesin. This protein has been shown to have a critical role in nasal 
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colonization mediated by the  NEAT domain, and the C-terminal of IsdA is responsible 
for cellular hydrophobicity [54,62]. IsdA is an important adhesin for both human and 
animal ligands [63]. An investigation of IsdA as a vaccine antigen for humans in 
combination with three other surface proteins IsdB, SrdD, and SrdE, was reported using 
the murine model. Effective protection was induced by the vaccine when mice were 
challenged with S. aureus, and modest opsonophagocytosis reported using serum 
antibodies [33]. In 2010, Kim et al., performed a passive immunization study using the 
mouse model with IsdA- and IsdB- specific antibodies. Protection against lethal 
intravenous S. aureus challenge was reported, and the group concluded that at least 
partial protection was achieved due to interference in pathogen’s haem sequestering 
mechanism [64]. An immunogenicity trial in mice, conducted in the Tinker lab, was 
reported using cholera toxin adjuvant conjugated IsdA (IsdA-CTA2/B). Mice were 
mucosally immunized with IsdA-CTA2/B chimera and humoral and cellular immune 
responses detected. Results from this study revealed the induction of Th2-type immune 
responses that were IsdA specific, showing significant immunogenicity and supporting 
the potential of IsdA as a vaccine antigen [65].  
ClfA 
ClfA is one of the first identified conserved S. aureus adhesins to be considered as 
a vaccine candidate alone or in combination with other proteins. This surface protein has 
since been extensively studied and validated as a promising vaccine target and has been 
licensed by several companies for inclusion into vaccines [66]. In 2001, Josefsson et al. 
reported that mice immunized with recombinantly produced ClfA developed less severe 
S. aureus arthritis than controls. In addition, passively immunized mice with ClfA 
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antibodies showed protection, indicating that protection in active immunization is 
antibody (Ig) mediated [56]. Passive immunization with SA-IGIV (Inhibitex, Inc) 
polyclonal anti-ClfA antibodies were able to recognize ClfA from S. aureus and inhibit 
adherence to FG up to 95% in vitro. SA-IGIV also promoted efficient 
opsonophagocytosis in vitro, by opsonizing ClfA coated fluorescent beads, which further 
facilitated their phagocytosis by human polymorphonuclear leukocytes. Furthermore, a 
combination therapy, using SA-IGIV and vancomycin revealed that the clearance of 
bacteremia was significantly higher in combination with SA-IVIG than vancomycin 
alone [67,68]. Studies have revealed that there is a requirement of host FG and S. aureus 
interaction for establishing septicemia, making ClfA an extremely important vaccine 
target [66,69–71]. Despite these many established reports supporting the antigenicity of 
ClfA, a contradictory study was recently reported by Li et al.. In this study, the efficacy 
of anti-ClfA responses was tested preclinically in rodent and rabbit models. 
Immunizations with ClfA induced functional and opsonic antibodies, which were able to 
inhibit binding of S. aureus to FG, however only modest reductions in abscess formation 
were seen after infection with S. aureus USA 300 [58]. It was also reported that neither 
ClfA, nor passively administered ClfA antibodies, could protect against S. aureus 
bacteremia or endocarditis in rat models. Furthermore, when mice were challenged with 
S. aureus intraperitoneally after immunization with ClfA or ClfA antibodies, slight 
increases in bacteremia were observed in experimental murine models as compared to 
controls [58]. These contrasting results have been described by others as overly 
simplistic, with an improper focus on one antigen [72]. Thus, despite that potential 
challenges need to be addressed, ClfA remains a top vaccine candidate for a human 
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vaccine, and also for the prevention of veterinary diseases like bovine mastitis. ClfA in 
combination with FnbpA was recently incorporated in a DNA/protein based vaccine, that 
is reported to induce partial protection of mammary glands in S. aureus mastitis [73,74] 
IsdB 
IsdB is also a highly conserved cell wall anchored protein from S. aureus that 
binds to haemoglobin and aids in iron sequestration. This protein has also been studied 
extensively as a vaccine target and is under much scrutiny due to a recent failed human 
vaccine trial. In 2006, Kuklin et al., from Merck Research Laboratories, reported a 
clinical trial on murine and rhesus macaque models with a vaccine consisting of IsdB + 
amorphous aluminum hydroxy phosphate sulfate adjuvant. Results showed up to a five-
fold increase in Ig titers after a single dose, and investigators described IsdB as an 
excellent S. aureus antigen, with reproducible and significant protection in animal models 
of infection [75]. Another report, investigating the role of cellular immunity in IsdB-
mediated protection in severe combined immunodeficient (SCID) mice, determined  the 
importance of TH17/IL-17 in IsdB mediated defense [76]. In 2014, A Phase IIB/III 
randomized placebo-controlled trial of the Merck V710 (Merck Sharp&Dohme Corp) S. 
aureus vaccine comprised of nonadjuvanted IsdB was conducted on 52 patients divided 
into 4 groups (2 placebo and 2 vaccinated) prior to elective cardiothoracic surgery. 
Reportedly, the vaccine failed to reduce the rate of post-operative S. aureus infections, 
and increased the mortality among patients who developed systemic S. aureus disease 
[77]. Later the pathophysiology around the results of the failed vaccine trial was 
explained as associated with extremely low IL2 levels in deceased patients prior to 
vaccination. In addition, the use of a single antigen and a focus on post-operative S. 
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aureus infection complicated study results [78]. The explanations regarding this failed 
vaccine trial can be due multiple other associated factors, one of them being the 
importance of the pre-clinical models used. Mouse immune and cardiovascular systems 
respond very differently to vaccines, and to S. aureus infection, than human systems. 
Current preclinical research on S. aureus vaccines is thus moving away from the use of 
rodents [79].  
EsxA  
EsxA is a secreted immune evasion protein and virulence factor responsible for S. 
aureus abscess formation [22]. EsxA is a part of the S. aureus Ess (ESX secretion) 
secretory pathway that contains a cluster of eight 
genes:  esxA, esaA, essA, essB, esaB, essC, esaC, and esxB [80]. EsxA has been 
characterized as a good vaccine antigen, and is included in vaccines alone or in 
combination with other antigens. EsxA is known to induce specific antibodies in sera of 
multi-drug resistant S. aureus infected patients [81]. In 2015, Bagnoli et al., from 
Novartis Research Laboratories reported a clinical trial using a vaccine containing five 
antigens (EsxA, EsxB, HlA, FhuD2 and conserved staphylococcal antigen 1A) with 
TH1/TH17 adjuvants [82]. The vaccine stimulated functional and opsonophagocytic 
antibodies and provided consistent protection in mice challenged with various strains of 
S. aureus. EsxA protein was also included in a one dose four component (4C)-
Staphylococcus vaccine that is reported to induce protection in S. aureus mouse models 
through the combined actions of antibodies, CD4+ effector T cells, and IL-17A [83]. 
Overall the trials and studies on EsxA have shown promising results however, more 
exploration is required for its application in human and veterinary vaccines. 
15 
 
 
 
IsdC 
IsdC is a member of the  Isd family of proteins that aid in transfer of haem across 
the cell membrane [30]. It is also a strongly conserved protein that has potential to be 
used as a vaccine antigen. IsdC contains one near-iron-transporter (NEAT), domain 
similar to IsdA. In S. lugdunensis, it is shown that IsdC is required for biofilm formation 
in low iron conditions, for primary cell-to cell attachment and accumulation phase of 
biofilm formation [84]. Hence IsdC is an important virulence factor for S. aureus and has 
good potential to be used as a vaccine antigen. 
Current Vaccines Against S. aureus Human Disease 
Currently there is no licensed vaccine for S. aureus human infection. Two 
vaccines: StaphVAX (Nabi Biopharmaceuticals) and V710 (Merck Sharp&Dohme Corp) 
and 4 passive immunization preparations have completed clinical trials toward FDA 
approval. StaphVAX is composed of capsular polysaccharide 5 (CP5) and CP8 
conjugated with recombinant exoprotein A (rETA) from Pseudomonas aeruginosa [85]. 
StaphVAX is reported to have failed in the reduction of S. aureus incidence in 
hemodialysis patients [86,87]. V710  provided protection against nasal carriage in a 
cotton rat model, increased survival of mice in a sepsis model and induced fivefold 
antigen-specific Ig titers [88]. Although in humans, as described above, V710 failed to 
reduce the incidence of post-operative S. aureus infection, and increased mortality in the 
vaccinated patients who had post-operative S. aureus infections [77]. The development 
and licensure of S. aureus human vaccines has been hampered by these two notable 
vaccine trial failures. Although there are evidences of single antigen vaccines working in 
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humans (Clostridium tetani, Corynebacterium diphtheriae; Tdap), it is widely agreed 
upon that the multi-antigen, or multivalent, approach will be essential for S. aureus. 
Bovine Mastitis  
Bovine mastitis is characterized by acute inflammation of the mammary tissues as 
a result of intra-mammary infection. This infection in mammary tissue is most often 
established by entry of the pathogen through the teat canal, commonly during the milking 
process, and dissemination into the mammary glands [89]. Establishing infection requires 
evasion of host innate immune defenses, such as: phagocytosis by neutrophils, 
elimination by milking, and the presence of lactoferrin in milk. Inflammation is the 
classical clinical sign of bovine mastitis, caused by bacterial proliferation in the 
mammary glands and induced by pro-inflammatory cytokines (IL-1β and TNF-α) at the 
site of infection [90]. Pathologically, bovine mastitis is defined by elevated somatic cells 
counts (SCC), at or greater than 2x105 cell/ml in milk, combined with the presence of the 
infecting pathogen [11]. The somatic cells most often seen in mastitis are neutrophils that 
have migrated to the mammary glands as a first line of host immune defense [10]. 
Geographical region contributes to strain specificity for S. aureus bovine disease, 
however, one region will have only a few strains causing  mastitis [91]. It has been 
reported that different quarters of the same udder can be infected with different strains of 
S. aureus, mount different levels of immune responses and have different severity of 
disease [92]. In addition, there are known risk factors defining the susceptibility of a cow 
to mastitis, such as: the stage of lactation, presence of lesions on teat skin, and the breed 
of cow [93–96]. The route of transmission is also an  important consideration that can 
contribute to progressive colonization and severity of infection [97]. It is known that if S. 
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aureus contaminates the teat orifice, it multiplies there and enters the teat canal for 
progressive colonization and dissemination. This infection occurs mainly by milking 
machine, and due to intra-mammary changes in pressure causing the bacterium to be 
transferred to the teat sinus [98].  
Infection of bovine mastitis can remain in the subclinical, or chronic, phase 
indefinitely, or it can alternate between clinical and subclinical disease. The progression 
of bovine mastitis is defined by three stages: 1) pathogen invasion, 2) infection and 3) 
inflammation [99]. In the invasion stage, the pathogen moves up the teat canal. In the 
infective stage, bacteria bind and adhere to mammary cells to establish infection in the 
gland cistern, divide and proliferate. In the final inflammatory stage, there is an increase 
in SCC, more cytokines are released and clinical signs of disease appear. As shown in 
Figure 1-2, the mammary glands of cows are anatomically designed to function as 
barriers of inoculation and progression of pathogens. The teat canal of the mammary 
gland is an important barrier and first line of defense against intra-mammary infection. 
Teat sphincter muscles in the canal keep the canal closed, so that the mammary gland is 
isolated from any potential infection of bacteria [100]. However, damage to the teat canal 
and teat skin can increase the risk of mammary gland infection. The surface of the teat 
canal contains fatty acids and keratin proteins that acts as a bacteriostatic agents [101]. 
Additionally, cationic proteins present in the teat canal can bind to pathogenic bacteria, 
increasing their susceptibility to the osmolarity of the canal [102]. If  bacteria penetrate 
the teat canal, they encounter the innate and adaptive immune responses, including: 
neutrophils, macrophages and lymphocytes [40]. The proinflammatory cytokines TNF-α 
and IL-1β are also released at the site of infection, stimulating the bactericidal activity of 
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neutrophils and macrophages, which in turn produce leukotrienes and prostaglandins to 
increase the local inflammatory reaction [103]. Epithelial cells of the mammary gland 
also play an important role in neutrophil recruitment to the infection site, adherence of 
bacteria and interaction with bacterial toxins [104]. Thus the innate and adaptive immune 
responses perform crucial roles in the pathophysiology of bovine mastitis, and these 
responses are regulated mostly by pro-inflammatory cytokines, increases in macrophage 
and neutrophil bactericidal activity, recruitment of neutrophils to the site of infection,  
and maturation DCs [105].  
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Figure 1-2. Inflammatory model of S. aureus caused bovine mastitis. A) The 
infective stage of S. aureus transfer through the teat canal and its colonization and 
movement through gland cistern and alveolus. B) The inflammatory phase, 
highlighting the magnified section of alveolus. The binding to S. aureus to mammary 
epithelial cells is shown, in addition to the internalization of S. aureus in macrophages 
and neutrophils plus the induction of inflammatory cytokines IL-1β and TNF-α. 
Physiological attributes associated with the mammary glands also make them 
more susceptible to S. aureus colonization and infection. Despite the high concentration 
of iron-binding proteins like lactoferrin, milk is an excellent, nutrient-rich, medium for 
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bacterial growth. In addition, the mammary glands of cows have reduced hydrolytic 
enzymes and phagocytic activity, to prevent the engulfment of milk components like 
proteins and fats [106]. This lack of phagocytosis prevents the engulfment of pathogenic 
bacteria as effectively as seen in other tissues of the body. In the absence of a strong 
phagocytic response, S. aureus adhesins can bind to the mammary gland epithelium and 
macrophages, to induce bacterial uptake and intracellular survival inside these cells 
[107]. Casein protein is in abundance in mammary glands due to the prevalence of milk; 
this  protein can coat the surface of neutrophils disabling their pseudopodia and hence 
their ability to translocate [108]. Complement proteins and opsonizing antibodies are low 
in abundance in milk and mammary tissues, which also helps bacteria to colonize and 
cause infection without stimulation of the complement system or opsonization. Lastly, it 
is reported that during the bovine pre-and post-parturition period there is a functional 
impairment of lymphocytic and neutrophilic activity due to stress, hormonal changes and 
lactation [109]. 
The pathogenicity of S. aureus in the mammary gland is a combined effect of 
virulence factors, specifically the ones that help in adhesion to host tissue, those that 
promote tissue damage and those that promote intracellular survival and evasion of host 
immune system. The virulence of some strains of S. aureus is dependent on growth phase 
and nutrient availability [110]. As described above, S. aureus produces a number of 
important proteins that bind to FN, FG and collagen, and these are involved in 
colonization of the udder. Lack of the adhesin, FnBP, causes a delay in internalization of 
S. aureus in mouse mastitic epithelial cells compared to the wild type [55]. Extracellular 
fibronectin binding protein (Efb) is studied for its immunogenicity in subclinical bovine 
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mastitis, in combination with FnbpA and ClfA, and shown to stimulate a strong humoral 
and mucosal immune response in vaccinated animals [111,112]. Eap/map virulence factor 
binds to ICAM-1 located at the surface of endothelial cells and blocks neutrophil binding 
to these cells [113]. Other virulence factors that contribute to disease progression and 
inflammation during mastitis include: exotoxins, bacterial super antigens, proteases and 
anti-phagocytic factors.  
The adhesive ECM molecules like FN, collagen, FG, laminin, vitronectin and 
elastin are present in the mammary gland and interact with bacterial adhesins, aiding in 
adherence and colonization [100]. FN exists in soluble and insoluble forms in the matrix 
and serves as a bridge between S. aureus and integrin-β1. This bridge, or contact, of S. 
aureus-to cell-to ECM is important to prevent apoptosis. After adhesion is established by 
S. aureus to mammary epithelial cells or MacTs, the integrin receptor starts the cascade 
of transduction events leading to uptake of bacteria [114,115]. Adherence to FN is 
essential S. aureus infection, and it has been demonstrated that using anti-FN antibodies, 
can significantly reduce adherence of S. aureus to  epithelial cells [116,117]. S. aureus 
FN-binding adhesins include FnbpA and IsdA, and these represent good bovine mastitis 
vaccine targets. 
Treatments and Prevention of Bovine Mastitis 
Bovine mastitis results in economic losses to dairy farmers due to poor milk yield, 
veterinary expenses, culling and discarded milk [118]. If bulk milk tank SCC is 400,000 
cells/ml, or higher, it is considered unfit for human consumption [119]. S. aureus, clinical 
or subclinical infection, is a major contributor to high SCC in bovines. Currently bovine 
S. aureus is treated with antibiotics, however, the cure rates are variable and often low 
22 
 
 
 
[120]. There are several parameters which determine the success of antibiotic treatment 
and cure. These include: higher than average increase in SCC, age of the cow, duration of 
infection, quarters of udder infected, resistance of strain, and bacterial load [121]. It is 
known that any quarter of the cow udder can be infected with S. aureus, and reports 
suggest that hind quarters have higher cure rates than front quarters [122]. Antibiotics 
found to deliver higher cure rates include: amoxicillin, erythromycin, cloxacillin, and 
pirlimycin [123]. The efficacy of antibiotic therapy for bovine mastitis varies between 
4% to 90%, depending upon the causal agent. S. aureus caused mastitis is among the 
most difficult to treat, with cure rates lower than 25% [124]. The unique ability of S. 
aureus to internalize in mammary gland epithelial cells or neutrophils/ macrophages 
affects the efficacy of antibiotics due to restricted access of innate and adaptive immune 
cells [125]. Furthermore, S. aureus is known to form biofilms in the udder, which also 
contributes to antibiotic resistance [126]. In addition to lower cure rates, there are other 
disadvantages of antibiotic use. Overuse or misuse of antibiotics can lead to the 
emergence of new antibiotic resistant strains of bacteria, which risks non-treatable 
infection, resistant strains in the food chain, and possibly the presence of antibiotic 
residues in cow milk. The cost of antibiotics and its long-term use impact animal health, 
agricultural economics and public health. 
Prevention of S. aureus mastitis with an effective vaccine would be a much 
preferable option over treatment. Developing a vaccine has proven to be difficult 
however, and those currently available provide limited efficacy and protection. Currently, 
there are two bovine S. aureus vaccines: Mastivac I (Ovejero Laboratories) and 
Lysigin/Somato-staph (Boehringer Ingelheim Vetmedica, Inc.). Mastivac, is a 
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commercially available vaccine, composed of fragments from three bovine clinical 
staphylococcal strains (VLVL8407; ZO3984 and BS449). This vaccine’s compositions 
are exosecretions of strains VL8407 and bacterial fragments of strains of ZO3984 and 
BS449 mixed with either incomplete Freund’s adjuvant (IFA) or ISA (SEPPIC, d’Orsay, 
Paris, France) [106,127,128]. Mouse trials using this vaccine did show immunogenic 
properties in addition to protection against homologous and heterologous S. aureus 
challenge, however, in bovine trials, only a slight reduction in new S. aureus udder 
infection was observed [106]. Lysigin (Boehringer Ingelheim Vetmedica, Inc.) is another 
commercially available vaccine for bovine mastitis, it is composed of a lysed culture of 
antigenic polyvalent somatic antigen containing S. aureus phage types I, II, III, IV and 
capsular polysaccharides [129]. This vaccine is capable inducing anti-staphylococcal 
antibodies in bovines, however it stimulated insufficient opsonizing antibodies in milk to 
facilitate phagocytosis and clearance of S. aureus from the mammary gland [130]. 
Induction of opsonizing antibodies is an important attribute of an effective S. aureus 
vaccine [131]. 
While current vaccines are reported to reduce the incidence of S. aureus caused 
bovine mastitis, they were not capable of complete prevention or elimination of 
transmission, and are not commonly used by dairy farmers in the U.S. An effective 
vaccine for S. aureus caused bovine mastitis thus still remains a top priority for the dairy 
industry. As stated above, the success of an S. aureus vaccine will depend upon the 
inclusion of multiple relevant antigens, and importantly, the success of such a vaccine 
will also depend upon induction of an effective immune response. For subunit based 
vaccines, the use of the correct adjuvant, to aid in proper antigen presentation and 
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enhancement of the immune response to make memory responses and induce long term 
efficacy, is essential. As described below, cholera toxin (CT) is a unique and promising 
vaccine adjuvant that may be effective to prevent bovine mastitis.  
Cholera Toxin as an Adjuvant for Subunit Vaccines 
Bacterial enterotoxins like: CT, heat labile toxin (LTI, LTIIa, LTIIb) and shiga 
toxin (Stx1 and Stx2), have long been studied as vaccine adjuvants. CT is a secreted AB 
type enterotoxin from Vibrio cholerae that is responsible for the watery diarrheal clinical 
outcome of disease. CT is composed of a larger heteromeric A subunit (240 amino acids; 
MW 28 kD) located centrally, and five homomeric B subunits (103 amino acids; MW 11 
kD) located peripherally [132]. The A subunit consists of two domains (Al and A2) and 
the upper A1 domain is held above the plane of the doughnut-shaped pentameric B 
subunits by the tethering A2 domain. The A1 domain is essential for enzymatic activity 
and conducts ADP ribosylation within the host cell. The five B subunits act as a receptor 
for cell entry by high-affinity binding to GM1 ganglioside present at the cell surface 
[133]. GM1 gangliosides are expressed ubiquitously on the surface of antigen presenting 
cells (APCs), macrophages, dendritic cells (DCs), natural killer cells (NK cells), 
epithelial cells and B cells [134].  
V. cholerae colonizes the intestinal epithelium, and once attached, the bacterium 
secretes toxin. CT is activated by host proteases (“nicking”) prior to entry into the cell 
[135]. As shown in Figure 1-3, once bound to host GM1, CT is transported into the 
endosomes, and moved in a retrograde path through the Golgi apparatus to the 
Endoplasmic Reticulum. The ER considers CT an incorrectly folded protein and degrades 
it using ER associated degradation (ERAD) [136]. Once degradation occurs the A subunit 
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crosses the ER membrane into the cytosol. The A1 subunit retains its native state in the 
cytosol and enzymatically triggers ADP ribosylation of Gαs. This results in an 
irreversible increase in the intracellular concentration of cAMP, activation of PKA 
(protein kinase A), and phosphorylation of the cystic fibrosis transmembrane receptor 
(CFTR) Cl- channel. The activation of CFTR leads to efflux of chloride ions out of the 
cell, causing massive water efflux, and the severe watery diarrhea that is characteristic of 
cholera disease [137].  
The translocation and stimulatory activities of CT toxin also make it an optimal 
vaccine adjuvant, especially for an intracellular and mucosal pathogen like S. aureus 
[138]. CT is immunogenic and is known to stimulate systemic and mucosal humoral and 
cellular responses [139]. CT can also potentiate the immunogenicity of most antigens, 
whether these are linked to or simply admixed with the toxin, provided that the antigen is 
given at the same time and at the same mucosal surface as the toxin [140]. Specifically, 
CT has been reported to induce: (i) the activation and permeability of the intestinal 
epithelium, leading to higher antigen uptake, (ii) increased antigen presentation by 
antigen presenting cells (APCs), (iii) the promotion of isotype differentiation of B cells to 
induce secretory IgA production, (iv) the promotion of stimulatory and inhibitory effects 
on cytokine production and (v) the upregulation of co-stimulatory molecules, such as 
MHC class II, to promote T cell differentiation.  
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Figure 1-3. Model of CT entry and trafficking. CT binds to the B subunit by GM1 
gangliosides. It then traffics through the early endosome to the Golgi apparatus and 
is eventually delivered to endoplasmic reticulum (ER). Once in ER the A1 subunit is 
unfolded and retro translocated by the ERAD pathway to the cytosol. Once in 
cytoplasm A1 subunit refolds into native form and activates adenyl cyclase and the 
increase in cAMP causes chloride secretion. 
Native Ct: Immunostimulatory Effects 
Induction and potentiation of APCs is one of the most important characteristics of 
an adjuvant [141]. Native, toxigenic CT has been shown to play a role in the maturation 
and induction of DCs in humans and mice [142]. B cells also play an important role 
establishing immunity by the production of antibodies and antigen presentation, it has 
been shown that when B cells are treated with CT they increase the induction of co-
27 
 
 
 
stimulatory signals required for activation of T cells by APCs [143–145]. Antigens 
conjugated to CT can be mucosally delivered faster and more efficiently to APCs, and 
this includes DCs, macrophages and B cells [140]. The stimulatory effects CT has on 
antigen presentation as well as the increase in the activation and migration of DCs 
suggests that CT is able to elicit both innate and adaptive immune responses through its 
actions on APCs. CT is also known to enhance T cell proliferation by increasing IL-12 
and IFN-γ cytokines when coadministered with an antigen [142]. In vitro studies indicate 
that a very small amount of antigen is required to stimulate a proliferative T-cell response 
when conjugated with CT [146]. Although the polarity of immune responses generated 
by CT is a matter of debate, some studies indicate that CT-treated DCs prime the naïve T 
cells in vitro and drive them towards a Th2 phenotype. However, a few studies report that 
the toxin induces a mixed Th1/Th2 type of immune responses [147].  
The success of any vaccine relies on the stimulation of unique antibodies against 
the antigen of interest and prevalence of those antibodies as an immunological memory 
[148]. B-cell antigen presentation is an important criterion in establishing an effective 
immune response with vaccines [149]. Current adjuvants have been chosen and designed 
based on their ability to elicit a cellular responses, specifically their abilities to induce a 
Th1, Th2, or Th17 cell response, as well as the amount of Ig produced [150]. CT has long 
been reported to induce antigen-specific IgG and IgA to co-administered antigens, 
however, little information exists regarding the ability of CT to influence immunologic 
memory [148]. More recently, Bemark et al., reported the memory-inducing capabilities 
of  CT on B cells in mice [151]. Another report has indicated that CT supports the 
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development of immunologic memory by proliferation and activation of lymphocytes 
within the (GCs) germinal centers [152].  
Non-Toxic CT Derivatives 
While native CT is the gold-standard, non-toxic CT derivatives have also been 
found to retain significant adjuvant activity. CT as compared to CTB showed enhanced 
antigen-presenting capabilities, suggesting a supportive role of toxicity  on antigen 
delivery [140]. However, it has been reported that B cells treated with CTB alone 
experienced an increase in the co-stimulatory signal required for T-cells activation. A 
recent study by Lundgren et al., showed that specific memory IgA antibodies against 
CTB were induced in the intestine by the oral CTB-based  cholera vaccine, Dukoral 
[148]. A non-toxic purified monomeric CTA1-DD (adjuvant) fusion protein, that contains 
the ADP-ribosylating enzyme from CT combined with the immunoglobulin binding 
domain of Staphylococcus aureus protein A, was shown to directly stimulate mast cells 
and to release TNF-α [153]. Mast cells are a promising target for adjuvants as they are 
located on the skin and throughout mucosal surfaces and act as a first line defense for 
many pathogens. Their location within the mucosal tissue combined with their newly 
found role for altering adaptive immune responses make them an interesting target for 
adjuvants [154]. This team also found that immunized mice had Ig half-lives that were 
two to three times longer than Ig from mice immunized with other adjuvants. 
Interestingly, the increase in Ab half-lives correlated with an increase in germinal centers 
(GC) activity [151]. 
While CTB clearly retains significant adjuvanticity, the mechanism of antigen 
conjugation or interaction, route of administration, and concentration of antigen/adjuvant 
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notably affect the immunstimulatory outcome. It has been reported that CTB directly 
conjugated to an antigen and  administered orally, nasally or sublingually at high 
concentrations, can induce tolerance more than the administration of antigen alone [155]. 
CTB has also been reported to induce autoimmunity to self-antigens and tolerance to 
autoimmune antigens, however, this seeming paradox is not currently well understood 
[156,157]. The most recent studies using CTB adjuvant have focused on the ability of 
CTB conjugates to act as proinsulin vaccines to suppress diabetes [158,159]. It remains to 
be determined if this versatility will be a benefit for the use of CTB-based adjuvants or a 
potential disadvantage.  
CTA2/B chimeras are toxin-based vaccines plus adjuvant that possess the GM1 
binding ability of the B subunit and the ER targeting (KDEL) motifs on the A2 subunit. 
These molecular possess the unique adjuvant qualities of CTB and are non-toxic [65]. 
The CTA2/B holotoxin-like molecule was first constructed in 1992 to develop an 
adjuvant that could be linked to the antigen of interest [160]. These molecules have since 
been reported as potential vaccines by a number of groups [161–170]. The Tinker 
laboratory has reported the construction a and purification of CTA2/B with the LcrV 
protective antigen from Yersinia enterocolitica and Y. pestis, making LcrV–CTA2/B 
chimeras [168]. This chimera showed the uptake and trafficking of the LcrV antigen like 
CTA2/B in vitro, reflecting the antigen-delivery  ability of the CTA2/B adjuvant [171]. 
CTA2/B chimeras have also been used as mucosal adjuvants in a subunit vaccine against 
S. aureus. In this report, the Tinker Laboratory developed an IsdA-CTA2/B chimera that 
stimulated significant humoral immune responses in mice after intranasal delivery [161] . 
Furthermore, a DIII-CTA2/B chimera, targeted against the West Nile Virus, was 
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constructed and found to induce antigen-specific IgM and IgA responses in mice [170]. 
In summary, the current data suggests that CTB and CTA2/B are highly immunogenic 
and can enhance specific immune responses when conjugated or co-expressed with 
antigens. However, further investigations to explore the mechanisms of action of these 
adjuvants including the potential to induce tolerance/autoimmunity, will allow more 
effective use of these molecules in future vaccines. 
Summary and Objectives 
Many studies and a few failures in human and veterinary vaccines have led to a 
growing belief that an efficacious vaccine for S. aureus infection will be difficult or 
impossible to achieve. Unraveling the pathogenic and evasion mechanisms of S. aureus 
will be important for the use of critical factors involved in these processes in vaccines. 
Although there is evidence with other pathogens that a single antigen vaccine can be 
effective, a multi-antigen vaccine approach will be essential for S. aureus. This is due to 
the complex pathogenicity and expression of many different virulence factors. An 
efficacious vaccine for S. aureus mastitis should include multiple highly conserved 
antigens to protect against various strains, and a safe and immunogenic adjuvant. 
Importantly, the vaccine must induce opsonizing antibodies, as well as cellular responses 
and be able to target mucosal surfaces.  
The overarching hypothesis of this research is that a mucosal, enterotoxin-based 
vaccine containing multiple relevant antigens will protect cows against S. aureus 
mastitis. To begin to address this hypothesis, the major aim of our research was to design 
a mucosal cholera toxin (CTA2/B) adjuvant based mucosal vaccine for S. aureus caused 
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mastitis. To achieve this aim, my dissertation work was focused on three distinct 
objectives: 
Objective 1: Expression, immunogenicity and variation of iron -regulated surface 
protein A from bovine isolates of Staphylococcus aureus 
IsdA is an important adhesin, virulence factor and invasin for S. aureus. It is 
reported to be conserved in human isolates and a good vaccine candidate. The 
determination of isdA genetic conservation and expression in bovine S. aureus is critical 
for its use in a bovine vaccine. The outcomes of this objective were threefold. These 
studies: 1) determined isdA conservation and IsdA expression from bovine S. aureus, 2) 
identified and characterized variants of IsdA and the binding capacity of these variants to 
FN and FG, and 3) identified the opsonizing ability of IsdA specific antibodies. 
Opsonophagocytosis is a critical property of antibodies essential for S. aureus vaccine 
efficacy.  
Objective 2: Immunogenicity of mucosal Staphylococcus aureus vaccine for 
bovine mastitis 
There is currently no effective vaccine available to prevent bovine mastitis. To 
develop a vaccine, the two conserved adhesins, IsdA and ClfA from S. aureus were used 
in combination with CTA2/B adjuvant. The immunogenicity of this chimeric vaccine was 
determined by two bovine trials completed during the dry off period. Milk and serum 
from cows were used to detect humoral and cellular immune responses in addition to 
detecting the opsonizing ability of vaccine-induced antigen specific antibody. The 
outcomes of this objective included: 1) the mucosal vaccine (IsdA-CTA2/B and ClfA-
CTA2/B) was able to stimulate humoral and cellular immune responses with largely a 
32 
 
 
 
Th2 bias, and 2) the antibodies stimulated against IsdA antigen were specific and capable 
of opsonophagocytosis. 
Objective 3: Immunoproteomics to identify Staphylococcus aureus antigens 
expressed in bovine milk during mastitis. 
S. aureus has many virulence factors required to adhere, invade, cause infection 
and aid in survival and proliferation. A multivalent vaccine that can be target the diseases 
associated with multiple strains and serotypes of the S. aureus will be more effective in 
preventing S. aureus caused mastitis. In this objective, two-dimensional electrophoresis 
(2DE) combined with mass-spectrometry was used for the detection of immunogenic 
virulence factors and surface proteins from S. aureus. The outcomes of this objective 
included: 1) the identification of 8 S. aureus surface proteins that are virulence factors 
and were immunogenic in bovine milk in vitro, and 2) the evaluation of two proteins, 
IsdC and EsxA as strong S. aureus vaccine candidates for incorporation into a bovine 
mastitis vaccine.  
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CHAPTER TWO: EXPRESSION, IMMUNOGENICITY AND VARIATION OF IRON-
REGULATED SURFACE PROTEIN A FROM BOVINE ISOLATES OF 
STAPHYLOCOCCUS AUREUS  
Abstract 
Staphylococcus aureus iron-regulated surface protein A (IsdA) is a FG and FN 
adhesin that also contributes to iron sequestration and resistance to innate immunity. IsdA 
is conserved in human isolates and has been investigated as a human vaccine candidate. 
The studies presented here describe the expression of isdA, the efficacy of anti-IsdA 
responses and the existence of IsdA sequence variants from bovine Staphylococcus. 
Clinical staphylococci were obtained from U.S. dairy farms and assayed by PCR for the 
presence and expression of isdA. isdA-positive species from bovines included S. aureus, 
S. haemolyticus and S. chromogenes. Immunoassays on bovine milk and serum 
confirmed the induction and opsonophagocytic activity of anti-IsdA humoral responses. 
The variable region of isdA was sequenced and protein alignments predicted the presence 
of two main variants consistent with those from human S. aureus. Mouse antibodies 
against one IsdA variant reduced staphylococcal binding to FN in vitro in an isotype-
dependent manner. Purified IsdA variants bound distinctly to FN and FG. These findings 
demonstrate that variability within the C-terminus of this adhesin affects immune 
reactivity and binding specificity, but are consistent with the significance of IsdA in 
bovine disease and relevant for vaccine development. 
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Introduction 
Staphylococcus aureus (S. aureus) is one of the most prevalent pathogens causing 
contagious subclinical and clinical bovine mastitis. Bovine mastitis is an inflammatory 
disease of mammary tissues in cows, often represented by marked increase in somatic 
cell count (SCC) [11,172–174]. Several pathogenic bacteria are known to cause bovine 
mastitis; however, S. aureus causes persistent, difficult or impossible to treat infections 
greatly impacting animal health [172–175]. This is the most economically important 
disease for the dairy industry, largely due to loss of milk and the cost of treatment [176]. 
In the U.S. alone, the economic loss by bovine mastitis is estimated to be approximately 
100-200$/cow [14,15,177,178]. The main treatment strategy adopted currently to treat 
bovine mastitis is the use of antibiotics and management practices at dairy farms. 
Excessive use of antibiotics is both a costly and risky option as it may lead to the 
emergence of new antibiotic resistant strains. Efforts have been made for treating and 
managing this disease, however, prevention by vaccination is the best approach. Effective 
protection with a vaccine for a variable pathogen like S. aureus will require a vaccine 
design which includes conserved virulence factors and determination of its antigenic 
variation. 
S. aureus possess a repertoire of virulence factors and surface adhesins, that 
enables its survival in the varied physiological conditions of the host [63,179]. Iron 
surface determinant (Isd) proteins are a class surface adhesins, that are involved in iron 
acquisition and ECM binding [27,180]. Iron is a critical nutrient for survival of S. aureus 
and its uptake is regulated by the FUR (ferric uptake regulator) regulator, in low iron 
conditions [41]. The NEAT (near iron transporter) domain of  Isd proteins is involved in 
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haem binding from haemoglobin, for uptake into the bacterial cytosol [47,62]. As shown 
in Figure 1-1 Chapter 1, the transfer of haem from membrane to cytoplasm is performed 
by four or more Isd proteins (IsdA, IsdB, IsdC, IsdH) [44,181]. IsdA is one of the most 
conserved of these proteins [45]. It is known to be critical for nasal colonization in 
humans and provides hydrophobicity to the cells through a cell wall binding (LPTGX) 
motif, aiding in colonization of S. aureus on the skin [29,182]. The NEAT domain in 
IsdA is known to play a role in binding of IsdA to FN, however, the significance of the 
C-terminal of IsdA in ECM binding is still not well described [25,77]. The C-terminus of 
IsdA is involved in surface hydrophobicity, that confers resistance to the antimicrobial 
peptides and fatty acid of the human skin [54]. These reports indicate that IsdA is an 
important virulence factor for S. aureus that may contribute to infection in the bovine 
udder. 
The goals of this study were three-fold: 1) to determine the presence of isdA in 
bovine isolates of Staphylococcus, 2) to determine the expression of IsdA in vivo as 
determined by qPCR and anti-IsdA immune responses, and 3) to identify IsdA sequence 
variation. Two main sequence variants were distinguished and the difference in binding 
specificities and immune activity of the two distinct isdA allelic variants was defined. 
The results of this study support the incorporation of the IsdA antigen in a multivalent 
bovine vaccine, however, it is acknowledged that variability of this antigen will be an 
important consideration for vaccine design. 
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Materials and Methods 
Bovine Milk, Serum and Staphylococcal Collection 
Blood and quarter milk were taken from observationally healthy lactating 
Holstein cows from Dairy 1 (D1; n = 53) and Dairy 2 (D2; n = 50) in the Northwest 
USA. All bovine sample collection protocols were pre-approved by the University of 
Idaho Institutional Animal Care and Use Committee (IACUC). SCCs were determined 
using the Delaval method (Tumba, Sweden). Milk (100 μl) was plated on mannitol salt 
agar (MSA) and MP2 Agar (Udder Health Systems Inc., Tacoma WA, USA) and cultured 
at 37◦C for 24 h. Samples with yellow growth on MSA plus growth in the absence of 
esculin hydrolysis on MP2 were presumptive staphylococci. Cultures were incubated in 
lysis buffer (20 mM Tris Cl, 2 nM EDTA, 1.2% Triton X-100 + 20 mg/mL lysozyme, pH 
8.0) for 30 min at 37◦C prior to DNA extraction (DNeasy, Qiagen, Valencia, CA, USA). 
Milk was centrifuged to remove fat layers. Blood was allowed to coagulate at room 
temperature. Milk and serum were diluted 1:10 in protease inhibitor (1:100 Thermo-
Fisher HALT, 5% glycerol in 1× PBS) and frozen at −20◦ prior to ELISA. An additional 
25 bovine Staphylococcus aureus isolates from clinically mastitic cows on 15 farms in 
six US states were obtained (Udder Health Systems, Inc.) These strains had been 
analyzed by mass spectrometry (MALDI). Species identification of all staphylococci was 
confirmed by 16S rRNA sequencing (GE Healthcare, SeqWright, Houston, TX, USA). 
Gene presence/absence was determined by electrophoresis of PCR performed under 
optimized conditions, and amplicon sizes are as indicated (Table 2-1). 
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Table 2-1. Bacterial strains, plasmids and primers used in this study 
Bacterial strains 
  Genotype or characteristics Reference or source 
 E. coli TE1 
S. aureus Newbould 305 
∆endA derivative of TX1 (8) 
  Bovine clinical isolate 
(8) 
(9) 
 S. aureus MRSA USA300 
S. aureus MRSA252 #75 
  Human clinical isolate 
  Human clinical isolate 
(10) 
(11) 
Plasmids 
  Gene Vector Reference or source 
 pBA015 
pBA009A 
pCK001 
isdA (MRSA252) 
isdA (MRSA252) 
isdA (Newbould) 
pET40(b) 
pTRCHisA 
pTRCHisA 
(11) 
(11) 
This study 
Primers 
  Gene Amplicon
(bp) 
Reference or Source 
 FW CGGTTCAACCAAAACCTGCT 
RV GCGAAGGCAACTGTGCTAAT 
isdA 380  This study 
 FW CAAATGGCGAAGCACAAGCAG 
RV CAAATGGCGAAGCACAAGCAG 
isdB 138 This study 
 FW AGCAGCACTGCAACAAATCC 
RV CCATGGACCATTGGATCT 
isdH 557 This study 
 FW CCTATGCCAGTAGCCAATGTC 
RV GCACCAAGCAGGTTATGTC 
clfA 318 This study 
 FW GTGAAAAACAATCTTAGGTAC 
RVTATCAATAGCTGATGAATCCG 
fnbpA 1750 (12) 
 FW GCGATTGATGGTGATACGGTT 
RV AGCCAAGCCTTGACGAACTAAAGC 
nuc 270 (13) 
 FW GGGATCATAGCGTCATTATTC 
RV AACGATTGTGACACGATAGCC 
mecA 527 (14) 
 FW GGCCGTGTTGAACGTGGTCAAATCA 
RV TACCATTTCAGTACCTTCTGGTAA 
tstaG 370 (15) 
 FW 8F AGAGTTTGATCCTGGCTCAG 
RV 534R ATTACCGCGGCTGCTGGC 
16s rRNA 530 (16) 
 
RT-PCR, ELISA, Western Blot and Opsonophagocytosis 
Total RNA was isolated from milk as described [183]. Briefly, milk was 
centrifuged at 3000 × g for 15 min at 4◦C and pellets washed (1× PBS + 0.5 mM EDTA). 
RNA was extracted (RNeasy, Qiagen), with an additional DNase (Promega, Madison, 
WI) treatment (1U/100 μL, 30 min). cDNA was transcribed as described by the 
manufacturer (High Capacity cDNA RT kit, Thermo Fisher) and included no RT 
controls. 16S rRNA and isdA PCR were conducted on 2 μL of cDNA with primers (Table 
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1) and GAPDH control. PCR (15 μL) was analyzed on 1% agarose with positive 
(Newbould 305) and negative (no template). For milk and serum ELISA, a HIS-IsdA 
fusion (pBA015, Table 2-1) was purified with cobalt chromatography as described [161]. 
Plates (Nunc, Thermo-Fisher) were coated with 50 μL of 10 μg/mL IsdA, and incubated 
for 12 h at 4◦C followed by washes (1× PBS + 0.05% Tween 20). Blocking buffer (1× 
PBS + 1% skim goat milk) was added for 2 h at 37◦C. Twofold dilutions, starting at 1:2 
for milk and 1:10 for serum, were added and incubated at 4◦C for 12 h prior to washing 
and addition of HRP-anti-bovine IgG (1: 10,000 Bethyl Laboratories, Montgomery, TX, 
USA). Samples were developed with tetramethylbenzidine (TMB One, Thermo-Fisher). 
Endpoint titers were defined as the reciprocal of the dilution giving an OD of 0.2. 
Staphylococcus + and isdA ± cows used in ELISA are shown (Table S1, Supporting 
Information). Ten cows from each farm, with both high and low SCC, and negative for 
Staphylococcus by culture, were also assayed (Staphylococcus–isdA–). ELISAs are by 
quarter for milk and by cow for blood. For westerns, IsdA (pBA015, 62 kD) was 
separated on 12% SDS-PAGE, transferred to nitrocellulose strips and incubated in 
blocking buffer (0.05% Tween-20 + 5% skim milk + 1× PBS) before probing with milk 
at 1:500. HRP-antiboxing IgG (1:5000 Bethyl Labs, Montgomery, TX) was added and 
strips were developed with Immobilon Western HRP substrate (Millipore, Billerica, MA, 
USA). Opsonophagocytosis (OSP) was performed as described by [131] with the addition 
of purified IsdA. IsdA (pCK001) was purified using cobalt as above for pBA015. Equal 
volumes of 50 μg heat-inactivated serum were mixed with 50 μg purified IsdA and 
incubated for 1 h at 37◦C. Equal volumes of S. aureus Newbould 305 (2 × 106) and 
bovine PBMCs (2 × 106) were added to the reaction and incubated at 37◦C. At 60 min, 
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cells were plated on MSA in triplicate. Results are reported as bacterial survival in 
CFU/mL and compared to survival without PBMCs. 
Table S1. Staphylococcus species from Dairies 1 
and 2 
CowID QTR MP2a CTb isdAc Sequence IDd 
D1-02 FL γ - - S.agnetis 
D1-07 BR γ - - S.xylosus 
D1-07 FL γ - + S.chromogenes 
D1-07 FR γ - - S.haemolyticus 
D1-13 BL γ - + S.spp 
D1-13 FR γ - - S.spp 
D1-14 FL α - - S.chromogenes 
D1-17 FR β - + S.haemolyticus 
D1-20 FL β + + S. aureus 
D1-26 FR γ - + S.chromogenes 
D1-43 BR γ + - S.agnetis 
D1-43 FR β - + S.haemolyticus 
D1-49 FL β - - S.saprophyticus 
D1-49 FR α - - S.xylosus 
D2-25 FL β - - S.chromogenes 
D2-25 BL β/α - - S.chromogenes 
D2-34 BL β - + S.devrise 
D2-34 BR β - + S.haemolyticus 
D2-37 FL β + + S. aureus 
D2-37 FR β/α - + S.haemolyticus 
D2-37 BL β - + S.haemolyticus 
D2-37 BR β - + S.haemolyticus 
D2-38 FL β - - S.haemolyticus 
D2-38 BR β + + S. aureus 
D2-41 FL β - + S.haemolyticus 
D2-41 BR β/γ - - S.haemolyticus 
D2-43 FL β - + S. aureus 
D2-43 FR α - + S.haemolyticus 
D2-43 BL β - - S.haemolyticus 
D2-43 BR β - + S.haemolyticus 
D2-44 FL β - + S.haemolyticus 
D2-44 FR β - - S.haemolyticus 
D2-44 BL β/γ - + S.haemolyticus 
D2-47 BL β - - S.haemolyticus 
a Hemolysis on MP2 
b coagulase tube 
c isdA PCR 
d 16S rRNA sequence 
 
Sequence Alignments and Predicted Tertiary Structure 
The variable region of IsdA was predicted to comprise amino acids 222–308 
(NCBI). Primers that encompass this region were used for isdA PCR and sequencing (GE 
Healthcare). Alignments and evolutionary analysis were completed in MEGA 7 [184]. A 
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rooted dendrogram of exhaustive pairwise IsdA alignments of 53 sequences (Table S2, 
Supporting Information) was constructed using maximum likelihood based on the JTT 
matrix-based model [184]. The I-TASSER server was used to visualize predicted IsdA 
tertiary structures [50]. Model templates included the S. aureus hemoglobin-IsdH 
complex and the NEAT domain of IsdA from S. aureus [185–188]. The Newbould 305 
model has a C score of –1.93 (estimated TM score of 0.48 ± 0.15), and the MRSA252 
model has a C score of –2.46 (estimated TM score of 0.43 ± 0.14). In the I-TASSER 
server, the range of C scores is –5 to 2, with >–1.5 indicating correct global topology. 
Table S2. IsdA sequences for phylogenetic analysis 
Strain  Host Variant Accession 
Newbould 305  cow I EJE55319 
RF122  cow I Q2YX95 
LGA251 cow II CCC87810 
112808A  cow III EOR47976 
CVMN26035PS chicken I KST23617 
S54F9 pig III KPA00104 
K12PJN53 pig II KII21536   
SA7112 pig III KST55542  
S123 pig III EPZ10793      
ST772-MRSA-V human I ABX29083 
TCH130 human I 253728336 
TW20 human I CBI49003 
JKD6008  human I ADL65130 
ST228  human I CCJ22550 
Newman  human I BAF67313 
CN1 human I AGU61191 
Z172 human I AGY89229 
04-02981 human I ADC37297 
A8796 human I EFH35863  
CGS01 human I 315196851 
CIGC348 human I EHT89412 
FCFHV36 human I AKA99128 
Gv69 human I AIU85137 
NRS100 human I AHW66048 
MRGR3 human I EOR40242 
MRSA S4 human I KSA20724 
MRSN 2761 human I KKJ47858 
TCH959 human I KLM30023   
USFL270 human I CFE56532 
DAR4145 human I AJE64530 
MSSAT145 human I SCS53121 
08-02300 human I ANI74018 
6850 human I AGU54846 
JKD6159 human I ADL22931     
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MO13 human II AEV78123 
SA268 human II AII55584 
ST1413 human II EWC67239 
MRSA252 human III CAG40105 
CIGC341D human III EHT84578 
CIG149 human III EHT78741  
08BA02176 human III AFR73148 
TCH60  human III ADQ77565 
DR10  human III EIA14898 
71193 human III AFH69349 
S100 human III EPZ05864 
VET0293R human III EZS55766 
ST20130939 human I AMV90129 
CA-347 human - AGO29398 
SK1585 human - KFD32297 
UK2 human III WP054190280 
S. aureus subsp. anaerobius human - KKI67573 
S.schwertzeri human - CDR24069 
S. argenteus human - WP000160870 
 
Anti-IsdA Mouse Serum 
Mouse immunization protocols were pre-approved by the Boise State University 
IACUC. Immunizations were performed as described  [161]). Briefly, two groups of six 
female BALB/c mice, 7 to 9 weeks old (Taconic, Hudson, NY), were administered 17 μg 
purified IsdA (MRSA252 variant III, pBA009) + 5 μg native cholera toxin (CT, Sigma 
Aldrich, St. Louis, MO, USA), or mock (PBS) in 10 μL 1XPBS applied to each nare by 
pipette under light anesthesia on days 0 and 10. Blood samples were obtained by lateral 
tail vein on day 14. Blood was allowed to coagulate and serum diluted 10-fold in protease 
inhibitor (as above). IsdA-specific antibodies in serum were analyzed by ELISA as 
described and endpoint titers defined as the reciprocal of the dilution giving an O.D. of 
0.2 [65]. 
Adhesion Blocking and Ecm Binding Assays 
For blocking assays, black walled (Nunc, Thermo-Fisher) 96-well plates were 
coated with 50 μL of 10 μg/mL bovine FN (R&D Systems, Minneapolis, MN, USA) for 
12 h at 4◦C. A 1:100 dilution of heat inactivated pooled mouse serum was mixed with 1 × 
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108 CFU of S. aureus MRSA252 or Newbould 305, grown in low iron media (LIM: 2 g 
NaCl, 1.2 g NaHCO3, 1.6 g yeast extract, 6 g protease peptone/400 mL), for 30 min at 
37◦C. A portion of 100 μL of the mixture was added to plates coated with FN and 
incubated at 37◦C for 12 h prior to washing and addition of 150 μL Alamar Blue (0.1% 
reazzurin in 1× PBS). Plates were read at 530/590 nm after 24 h. For binding assays, 
IsdA from pBA009A and pCK001 was purified as above and separated on 12% SDS-
PAGE. Purified IsdA (100 μg) was added in 2-fold dilutions to 96-well plates coated with 
10 μg/mL bovine FN or bovine FG (Alfa Aerar, Reston, VA, USA) and incubated at 
37◦C for 12 h prior to washing and addition of mouse anti-HIS (1:1000 Sigma) and anti-
mouse HRP secondary (1:10 000 Promega). Plates were developed (TMB One) and read 
at 370 nm. 
Graphing and Statistical Analysis 
Graphing and statistical analysis was performed with JMP SAS software (Cary, 
NC, USA). PCR and RT-PCR are representative of three independent assays; ELISAs are 
reported as the means of three independent assays; and the OSP, adhesion and FN/FG 
binding assays are triplicate means of one assay that is representative of three 
independent assays. Significance for ELISA was determined using the non-parametric 
Wilcoxon rank score (Mann-Whitney) test. Significance of OSP and adhesion assays was 
determined using Student’s t-test. P-values are reported as P ≤ 0.05(∗), P ≤ 0.01(∗∗) or P 
≤ 0.0001(∗∗∗∗). 
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Results 
Presence and Expression Of isdA In Bovine Isolates of Staphylococci 
Blood and milk were obtained from 103 cows at two US dairies that differed in 
size and operation. Presumptive staphylococci from milk were assayed by PCR for the 
presence of isdA and 16S rRNA species identification. Four isolates of 34 (12%) were 
Staphylococcus aureus and 19 were isdA positive (56%). Twenty-five additional clinical 
bovine S. aureus isolates were obtained. The presence of isdA, and six additional 
virulence factors, was assessed by PCR in all staphylococci (Table 2-2). isdA was 
conserved in S. aureus (total of 28/29, 96.6%), and also present in S. haemolyticus 
(11/17, 64.7%), S. chromogenes (2/5, 40%) and S. devreise (1/1, 100%). isdB was 
conserved in all S. aureus (29/29, 100%), and other species harboring isdA. The adhesin 
clumping factor A (clfA) was also highly conserved (28/29, 96.6%). To determine the 
expression of isdA during mammary infection, we identified the presence of isdA mRNA 
from total milk RNA. As shown in Fig. 2-1A, the majority of isdA positive 
staphylococci-infected milk samples (Staphylococcus+ isdA+) contained isdA mRNA. 
The staphylococcal culture from 14FL (D1) was negative for isdA by PCR, and the milk 
sample was negative by RT-PCR. Two Staphylococcus +isdA+ samples had low CFUs, 
and were inconclusive by RT-PCR (D1-26FR and D2-43FL). The expression of IsdA in 
vivo was assessed by anti- IsdA ELISA of milk and serum. As shown in Figure 2-1B and 
C, Staphylococcus+ isdA+ milk and serum samples had heightened anti-IsdA IgG 
responses over samples negative for Staphylococcus (Staphylococcus– isdA–). A western 
blot of purified IsdA probed with Staphylococcus+ isdA+ milk (cows D2 43FR and D2 
37FR) compared to Staphylococcus – isdA – milk (cows D2 1FL and D2 6FL) supported 
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the immunogenicity of IsdA in vivo (Figure 2-1D). To assess the efficacy of anti-IsdA 
serum antibodies, we determined OSP of S. aureus Newbould 305 (Figure 2-1E). 
Bacterial cells were mixed with bovine PBMCs and Staphylococcus–isdA– serum (low 
anti- IsdA titer, light gray bars) or Staphylococcus +isdA+ serum (high anti-IsdA titer, 
dark gray bars). Serum was preincubated in the presence or absence of purified IsdA to 
block antibody activity. High anti-IsdA serum stimulated more bacterial killing than low 
anti-IsdA serum (P ≤ 0.05), and purified IsdA significantly blocked bacterial killing in 
the presence of high anti-IsdA serum (P ≤ 000.1). 
Table 2-2 PCR analysis of adhesins from bovine staphylococcal isolates 
Sequence ID # of 
tot
al 
isolates 
# positive isolates (percent positive) 
isdA isdB isdH clfA fnbpA nuc mecA 
S. aureus 29 28(96.6) 29(100) 25(86.2) 28(96.6) 25(86.2) 26(89.7) 0 
S. haemolyticus 17 11(64.7) 11(64.7) 0 0 4(23.5) 0 0 
S. chromogenes 5 2(40) 2(40) 0 2(40) 2(40) 0 3(60) 
S. agnetis 2 0 0 0 0 0 0 0 
S. xylosus 2 0 0 0 0 0 0 0 
S. devriesei 1 1(100) 1(100) 0 1(100) 0 0 0 
S. saprophyticus 1 0 0 0 0 0 0 1(100) 
S. spp. 3 1 (33.3) 1(33.3) 0 0 0 0 1 (33.3) 
Newbould 305  + + + + + +  
USA300  + + + + + + + 
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Figure 2-1. In vivo expression and immunogenicity of Staphylococcus IsdA from 
bovine milk and serum. (A) Expression of isdA from total RNA in bovine milk: RT-
PCR of (a) isdA (385 bps) and (b) 16S rRNA (530 bps). (B) IsdA-specific IgG 
responses in milk and (C) serum as determined by ELISA on samples obtained from 
Dairies 1 and 2. Samples are grouped as those from cows that were negative or 
positive by culture of Staphylococcus in milk and those that are negative or positive 
for isdA by PCR. Significance using the non-parametric Wilcoxon rank score test 
(Mann-Whitney), P ≤ 0.05(∗) or P ≤ 0.01(∗∗), between cow groups is shown. (D) 
Western blot (top) and corresponding SDS-PAGE (bottom) of anti-IsdA responses in 
milk. Purified IsdA (62 kD) was probed with Staphylococcus–isdA– (D2-1FL, D2-6Fl) 
and Staphylococcus +isdA+ (D2-43FR, D2-37FR) milk samples. (E) OPA of S. aureus 
Newbould 305 with PBMCs and serum from Staphylococcus –isdA– (light gray bars) 
and Staphylococccus +isdA+ (dark gray bars) cows. Significance using the pairwise 
Student’s t-test, P ≤ 0.05(∗) between serum types or P ≤ 0.0001 (∗∗∗∗) between 
treatment groups, is indicated. (Adapted from Misra et al. (2017) [184] ) 
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IsdA sequence analysis 
Comparison of published S. aureus IsdA indicates that 86 amino acids within the 
C-terminus are variable. This region is distinct from conserved iron-binding, heme-
binding and NEAT domains of IsdA, as well as the C-terminal cell wall sortase signal 
(Fig. 2-2A). The 380-bp variable region from all isdA +staphylococcal isolates were 
amplified for sequencing and alignment. Figure 2-2 shows IsdA alignments from 
staphylococci of the two dairies (B) and 23 S. aureus clinical isolates (C). One S. aureus 
was negative for isdA by PCR and one was isdA+ but sequence could not be obtained. 
Nucleotide differences within this region resulted in two main allelic variants that align 
with bovine (Newbould 305, variant I) and human (MRSA252, variant III) IsdA. 
Notably, variant III contains a characteristic four-amino-acid insertion near the C-
terminus. Predicted tertiary structure models were constructed using IsdA from 
Newbould 305 and MRSA252 (Fig. 2-2D) [50]. Models predict that the variable region 
of IsdA has a coiled secondary structure with a solvent accessibility of 3–7 (0 = buried 
residue, 9 = highly exposed). To determine if observed variation is consistent with human 
S. aureus IsdA, phylogenetic analysis was completed with 53 published sequences 
(Figure 2-3). Results included four cows, four pigs and one chicken isolate. Sequences 
were largely conserved; however, differences within the variable region resulted in 
clustering within two groups represented by MRSA252 (III, blue) and Newbould 305 (I, 
red). A smaller subgroup consisted of those that contained only the characteristic four-
amino-acid C-terminal insertion (variant II, green). Two strains (CA-347 and SK1585) 
are closely related to variant II, but do not contain this C-terminal insertion. 
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Figure 2-2. IsdA alignment and structure from bovine isolates. (A) Schematic 
representation of IsdA structure including the conserved NEAT domain (red), 
variable C-terminal regions (blue) and cell-wall-associated sortase signal (LPxTG, 
green). Predicted amino acid alignment of the IsdA variable region from (B) 19 isdA+ 
Staphylococcus from Dairies 1 and 2, and (C) 23 isdA + S. aureus from mastitic bovine 
milk across the USA, showing percent positive identity to S. aureus Newbould 305 and 
MRSA252. (D) I-TASSER predicted tertiary structures of IsdA from Newbould 305 
(variant I) and MRSA252 (variant III) S. aureus. Colors are representative of the 
same regions as those in A. (Adapted from Misra et al. (2017) [184], thanks to Tyler 
Wines for sequencing and alignment) 
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Figure 2-3. Dendrogram of pairwise IsdA alignments of 53 published sequences. 
Evolutionary analysis was performed with the maximum likelihood method based on 
the JTT matrix-based model (MEGA, Version 7). Variants align into three main 
groups, based on sequence differences within the variable C-terminus, representative 
of Newbould 305 (I, red), MRSA252 (III, blue) and LGA251 (II, green). Isolates from 
cow (∗), pig (∗∗) and chicken (∗∗∗) are noted. (Adapted from Misra et al. (2017) [184]) 
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Characterization of IsdA Variants 
To assess if genetic variation of isdA could contribute to differences in protein 
immune reactivity, we produced antibodies to variant III (MRSA252) in mice (Figure 2-
4A) and used pooled serum to block S. aureus adhesion to FN. Antibodies produced against 
variant III reduced FN binding of S. aureus MRSA252, but did not reduce binding of 
Newbould 305 (Fig. 2-4B). Variants I and III were purified from Escherichia coli and 
found to run at distinct sizes on SDS-PAGE (Figure 2-4C). ECM binding assays revealed 
that variant I (Newbould 305) and variant III (MRSA252) had consistently distinct 
interactions with FN, while variants bound similarly to FG (Figure 2-4D and E). 
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Figure 2-4. Characterization of IsdA variants. Immune reactivity of variants 
assessed by blocking S. aureus adhesion to FN in vitro with mouse antiserum. (A) IgG 
anti-IsdA titers from mice vaccinated with IsdA (variant III, MRSA252) or 
unvaccinated, and (B) adhesion of S. aureus Newbould 305 or S. aureus MRSA252 to 
FN after incubation with pooled mouse serum from mice vaccinated with IsdA 
MRSA252 (dark gray bars) or unvaccinated serum (light gray bars). Significance 
using Student’s t-test, P ≤ 0.01(∗∗), between serum types is indicated. Binding 
specificity of IsdA variants assessed by ECM binding assay: (C) SDS-PAGE of 
purified IsdA from Newbould 305 (lane 1) and MRSA252 (lane 2), and binding of 
purified IsdA from MRSA252 and Newbould 305 to (D) FN and (E) FG. (Adapted 
from Misra et al. (2017) [184], thanks to Liwen Yang and Colton Knopp for mouse 
study and FN binding assays) 
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Discussion 
S. aureus is a prevalent pathogen in humans and livestock [8]. This bacterium has 
been investigated for decades, but its mechanisms of virulence are still not fully 
understood. This study was aimed at evaluating IsdA as a potential bovine vaccine 
candidate. The expression and variation of IsdA from a number of bovine S. aureus was 
analyzed to advance the current understanding of its involvement in bovine disease. The 
results from this study generated a number of outcomes and observations, including: 1) 
the presence of isdA is strongly conserved in bovine S. aureus and it is also present in 
some species of coagulase negative (CNS) Staphylococcus, 2) isdA is expressed in milk 
from infected cows and induces antigen-specific responses, 3) anti-isdA antibodies are 
active to induce opsonophagocytosis, 4) due to amino acid variation within the C-
terminus, there are two-three main allelic variants of IsdA and 5) allelic variants bind 
differentially to ECM proteins, indicating that the C-terminus is important for FN 
binding.  Use of targeted and conserved antigenic proteins is an essential characteristic 
for a vaccine, especially for a highly variable pathogen like S. aureus, and this study 
advanced our understanding of one important antigen. 
While the presence of isdA in CNS strains of Staphylococcus indicates that this 
antigen is not species-specific CNS staphylococci are also known to cause mastitis, and 
infections are clinically relevant and may become chromic [189]. Other antigenic surface 
proteins like ClfA and IsdB were also determined in this study to be conserved at the 
genetic level, however, further characterization is required to investigate their 
antigenicity. IsdB and ClfA both are reported potential vaccine antigens for human 
vaccines [47,190]. Previous reports show a non-significant stimulation of immune 
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responses by IsdB in human vaccines, however ClfA could be further characterized as an 
antigen for bovine vaccine [77]. In this study, significant stimulation of anti-IsdA 
immune responses in milk and serum was detected from cows currently infected with 
isdA+ staphylococci, reflecting effective immune reactivity and surface exposure of the 
IsdA antigen. The gene expression of isdA in milk also indicated that it is surface 
exposed at the time of infection, further supporting its use as a target antigen for bovine 
disease. However, a major limitation is of this study is that milk and blood samples were 
taken at one time point, and no information is available on how long cows were infected, 
or if cows had been infected previously. Thus, the efficacy, and the relevancy, of anti-
IsdA antibodies was assessed by opsonophagocytosis assay (OPA). OPA using antibodies 
from serum of infected or uninfected cows shows stimulation of active immune responses 
against IsdA, which were able to uptake and trigger phagocytosis of S. aureus. These 
results indicate that IsdA is present and expressed from bovine Staphylococcus in vivo 
and that this antigen induces active immune responses in vivo.  
The NEAT domain of IsdA has a role in binding specificities and immune 
reactivity, whereas the C-terminus is responsible for conferring hydrophobicity [54]. The 
hydrophobicity provided by the C-terminus is very important for skin colonization of S. 
aureus [54]. The results from multiple alignments in this study determined that there is 
variation at the C-terminus of IsdA that results in the occurrence of two main allelic 
variants. This variation is a result of amino acid insertions and a proline to histidine 
substitution within the C-terminus. These allelic variants were represented by two 
different strains of S. aureus; bovine (I, Newbould 305) and human (III, MRSA 252), 
with variant I actually predominating in S. aureus isolated from both hosts. The NEAT 
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domain of IsdA is known to bind to FG, and it is mostly conserved [62]. FN binding 
experiments in this study, revealed that variation at the C-terminal influenced the binding 
specificities of allelic variants, which suggests that the role of the C-terminus of IsdA is 
to aid in the binding of FN. The limited sample size of this report however does not 
support the conclusion that allelic variants have preference for either bovine or human 
hosts. Current evidence suggests that that both allelic variants of IsdA may be important 
for ECM interactions in bovine disease. Overall, the work presented here supports the 
inclusion of  IsdA in a vaccine designed to combat S. aureus caused bovine mastitis, 
however, the incorporation of multiple alleles may be necessary.  
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CHAPTER THREE: IMMUNOGENICITY OF A MUCOSAL STAPHYLOCOCCUS 
AUREUS VACCINE FOR BOVINE MASTITIS 
Abstract 
Staphylococcus aureus causes a chronic, contagious disease of the udder, or 
mastitis, in dairy cows. This infection is often refractory to antibiotic treatment, and has a 
significant economic impact on milk production worldwide. An effective vaccine to 
prevent S. aureus mastitis would improve animal health, reduce antibiotic dependence 
and inform human vaccine approaches. The iron-regulated surface determinant A (IsdA) 
and clumping factor A (ClfA) are conserved S. aureus extracellular-matrix adhesins and 
target vaccine antigens. Here we report the results of two bovine immunogenicity trials 
using purified IsdA and ClfA-cholera toxin A2/B chimeras (IsdA-CTA2/B and ClfA-
CTA2/B). Cows were intranasally inoculated with IsdA-CTA2/B + ClfA-CTA2/B at dry 
off and followed for 70 days. Trial 1 utilized three groups with one or two booster doses 
at a total concentration of 600 or 900 g. Trial 2 utilized two groups with one booster at a 
total concentration of 1200 g. Humoral immune responses in serum, milk and nasal 
wash were examined by ELISA. Responses in serum were significant between groups 
and provide evidence of antigen-specific IgG induction after vaccination in both trials. 
Cellular proliferation was detected by flow cytometry using antigen-stimulated PBMCs 
from day 60 of Trial 2 and revealed an increase in CD4+ T cells from vaccinated cows. 
IsdA and ClfA stimulation induced Il-4 expression, but not IFN- or IL-17, in PBMCs 
from day 60 as determined by cytokine expression analysis. Opsonophagocytosis of S. 
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aureus confirmed the functional in vitro activity of anti-IsdA antibodies from Trial 2 
serum and milk. The vaccine was well tolerated and safe, and results support the potential 
of mucosally-delivered CTA2/B chimeras to protect cows from mastitis caused by S. 
aureus.  
Introduction 
Bovine mastitis is one of the most prevalent and economically impactful diseases 
of the dairy industry. The economic losses caused by this disease are estimated to be 
$1.7-2 billion annually in the U.S. [14,15]. Multiple pathogens are capable of causing 
bovine mastitis, leading to loss of milk yield and deteriorating animal health, however, S. 
aureus causes contagious and difficult or impossible to treat subclinical and clinical 
bovine mastitis [191,192]. S. aureus caused bovine mastitis is also of great concern due 
to increasing antibiotic resistance and overall decrease in cure rates, especially for β-
lactamase positive isolates [193]. It has been reported that approximately 4-10% of cows 
in U.S. are infected by S. aureus [174,194–196]. Management control practices on farms 
have been successful in decreasing the rate of infection, however, S. aureus is known to 
colonize skin and internalize inside mammary epithelial cells, alveolar cells, and 
macrophages, which can limit antibiotic efficacy and lead to chronic, difficult to treat 
subclinical infection [99]. An effective bovine S. aureus vaccine to reduce or eliminate 
disease and prevent transmission would have large impacts on both animal and human 
health [197–200]. 
There have been a number of attempts to design an S. aureus vaccine for bovine 
mastitis. Approaches like whole cell vaccines, live attenuated vaccines, DNA vaccines, 
toxoids, capsular polysaccharides and purified proteins have been used [129,201–204]. 
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Despite substantial progress, an effective vaccine that can protect cows against the 
multiple strains and serotypes of S. aureus that cause mastitis is still needed. It is well 
recognized that the use of multiple highly conserved and significant virulence factors will 
be necessary to induce inter-strain protection. Additionally, the route of vaccine 
administration and use of adjuvant for a mucosal and intracellular pathogen like S. aureus 
is critical. A vaccine delivered mucosally, that could induce mucosal humoral as well as 
cellular responses would reduce the colonization and adherence of S. aureus and aid in 
preventing chronic S. aureus mastitis.  
In this study, two bovine immunogenicity trials were performed to assess the 
activity of a subunit vaccine comprised of purified iron regulated surface determinant 
protein A (IsdA) and clumping factor A (ClfA) proteins combined with cholera toxin 
(CTA2/B) adjuvant (IsdA-ACT2/B +ClfA-CTA2/B). CTA2/B is a safe and immunogenic 
mucosal adjuvant from Vibrio cholerae made by genetically removing the toxic CTA1 
subunit [161,163,205]. CTA2/B is known to stimulate cellular and protective immune 
responses when co-administered with antigens [162–168, 203, 204]. 
We hypothesized that a CTA2/B adjuvant based mucosal vaccine would induce 
antigen-specific humoral and cellular immunity, and will aid in reducing colonization of S. 
aureus in the cow udder. Our results support the conclusion that intranasal administration 
of the IsdA-CTA2/B+ClfA-CTA2/B subunit vaccine during the dry period can stimulate 
significant antigen-specific immune responses in milk and serum and that the antibodies 
are active and capable of triggering opsonophagocytosis.  
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Materials and Methods 
Bacterial Strains, Growth Conditions and Plasmids 
Staphylococcus aureus Newbould 305 was used for the cloning of isdA and clfA 
and opsonophagocytosis assay (OPA)[206–208]. S. aureus was grown Luria Broth (LB) 
with shaking at 37°C for genomic DNA isolation and in low iron media (LIM) without 
shaking at 37°C for OPA [33]. E. coli TE1 was used for cloning and protein expression 
of HIS-tagged antigens from pCK001 and pMaH001 for ELISA (Table 3-1). These 
strains were grown in LB for cloning, or terrific broth (TB) for protein expression, + 100 
g/mL ampicillin at 37°C. E. coli Clear Coli BL21(DE3) (Lucigen, Madison, WI) was 
used for expression of CTA2/B chimeras from pLR001 and pLR003 and grown at 37°C 
in TB in presence of 35 ug/mL chloramphenicol. Plasmid pLR001 was constructed by 
amplification of Newbould 305 genomic DNA using isdA-specific primers and ligation 
into the vector pARLDR19 (SphI-ClaI) [169]. pLR003 was similarly constructed by 
cloning into pARLDR19 (SphI-XhoI) using clfA-specific primers. pCK001 was 
constructed by ligation of isdA from Newbould 305 into pTRCHIS (BamHI-HindIII) to 
express HIS-IsdA. pMaH001 was constructed by cloning of Newbould 305 clfA, using 
pLR003 as a template, into pBAD18 (NheI-HindIII) to enable expression of ClfA-HIS 
into the E. coli periplasm. Strains, plasmid details and primer sequences (with restriction 
sites underlined) are shown in Table 3-1. All plasmids were sequenced through cloning 
junctions for confirmation.  
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Protein expression and purification.  
Chimeras were purified as described [209]. Briefly, to express IsdA-CTA2/B and 
ClfA-CTA2/B, ClearColi® (Lucingen, Madison, WI) transformed with pLR001 or 
pLR003 was grown to an optical density (O.D.600) of 0.9 and induced for 24 h with 0.2 
% L-arabinose. Proteins were isolated from the periplasmic extract with 1 mg/mL 
polymyxin B and purified by affinity chromatography on immobilized D-galactose 
Table 3-1. Bacterial strains, plasmids and primers used in this study 
Bacterial strains 
  Genotype or characteristics Reference or source 
 E.coli TE1 
E.coli ClearColi® 
S. aureus Newbould 305 
∆endA derivative of TX1 [79] 
  Lipid IVA modification of BL21(DE3) 
  Bovine clinical isolate 
[79] 
Lucigen, Madison, WI 
[32] 
Plasmids 
  Gene Vector Reference or source 
 pLR001 
pLR003 
pCK001 
pMAH001 
isdA (Newbould ) 
clfA (Newbould) 
isdA (Newbould) 
clfA (Newbould) 
pARLDR19 
pARLDR19 
pTRCHisA 
pBAD18 
This study 
This study 
This study 
This study 
Primers 
 
Cloning 
pLR001:      FW    GCTACTGGCATGCGGCAACAGAAGCTACGAAC 
                     RV GTGCATGATCGATTTTGGTAATTCTTTAGC 
pLR003:      FW GACTGGGCATGCAGGTGTAACTTCAACTGCTAAAG          
                     RV GCATGGCTCGAGGGAATTGGTTCAATTTCACCAG 
pCK001:      FW GCTACTGGATCCGCGGCAACAGAAGCTACGAAC 
                     RV GTGCATAAGCTTTCAAGTTTTTGGTAATTCTTTAGC 
pMAH001:  FW GATCCTCGCTAGCGGATGGAGTAAGACCATGG 
                     RV GTACCAGAAGCTTTTAGTGATGGTGATGGT 
                               GATGGGGAATTGGTTCAATTTCAC 
 
Bovine cytokine qPCR: 
           FW GCATCGTGGAGGGACTTATGA 
           RV GGGCCATCCACAGTCTTCTG 
           FW CAGCATGGAGCTGCCT 
           RV ACAGAACAGGTCTTGCTTGC 
           FW CAGAAAGCGGAAGAGAAGTCAGA 
           RV  TGCAGGCAGGAGGACCAT 
           FW GCCCACCTACTGAGGACAAG 
           RV GCTGGATGGTGACAGAGTTC 
Gene Amplicon  Source 
 
isdA 
 
clfA 
 
isdA 
 
clfA 
 
 
 
 
GAPDH 
 
IL-4 
 
INF- 
 
IL-17A 
 
846 bp 
 
840 bp 
 
852 bp 
 
994 bp 
 
 
 
  
 
[21] 
 
This study 
 
[21]  
 
This study 
 
 
 
 
[80] 
 
[81] 
 
[80] 
 
[82] 
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(Pierce™ D-Galactose Agarose, Thermo Fisher, Waltham, MA). Vaccine proteins were 
dialyzed into sterile 20% glycerol + 1XPBS and protein concentrations determined by 
BCA (Pierce™ BCA, Thermo Fisher). Vaccines were tested to ensure endotoxin levels 
were below 0.05 EU/mL (LAL Endpoint Chromogenic, Lonza, Allendale, NJ) plated for 
sterility and stored at -80C until use. For use in ELISA, IsdA and ClfA from Newbould 
305 were isolated from the cytosol of E. coli Top10 (Thermo Fisher) containing pCK001 
and pMAH001 after overnight induction with 1M IPTG. Proteins were then purified on 
cobalt (HisPurTM, Thermo Fisher) under denaturing conditions and dialyzed into sterile 
1XPBS. For use in flow cytometry and OPA, endotoxin was removed from these proteins 
(PierceTM Endotoxin Removal Columns, Thermo Fisher). 
Animals, Trial Design and Sample Collection  
All animal protocols were pre-approved by the Boise State University 
Institutional Animal Care and Use Committee. Approval was obtained from the State of 
Idaho and USDA Center for Veterinary Biologics to transport exploratory vaccine. 
Sample size was determined prior to Trial 1 by power analysis based upon predicted 
immune responses in milk and serum. A sample size of 7 cows per group was predicted 
to provide, at a 95% level of confidence, 92% power to detect a minimum difference 
between the control and any other group of 15%. This was based on a univariate two-
group repeated measures analysis of variance (ANOVA), assuming that the between 
groups error term is 0.13 and the within-groups error term is 0.08 [210]. Healthy Holstein 
cows in the third or fourth lactation were enrolled in the study (21 total Trial 1, n =7; 22 
total Trial 2, n=11). Animals were initially screened as those with at least one of two 
previous somatic cell counts (SCC) counts below 200 x103 cells/mL and no clinical 
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evidence of mastitis. Further enrollment criteria included: 1) no growth of S. aureus 
culture from milk, 2) low baseline anti-IsdA responses in milk, and 3) no evidence of 
bovine leukemia virus (BLV) infection. Cows were randomized into two or three groups 
(Figure 3-2) and vaccinated on days 1, 14 and 49 (Trial 1) or 1 and 14 (Trial 2), and 
followed until calving (Day Fresh = day 60 or 70). One cow in Trial 1 (Group 2) and four 
cows in Trial 2 (Groups 1 and 2) left the study prior to day 60 due to unrelated 
complications. Milk was not obtained from two additional cows in Trial 1 (Groups 1 and 
3) because they did not freshen by day 70. The vaccine was delivered in 2.5 mL volumes 
into each nare using a nasal cannula (Merck & Co., Kenilworth, NJ). Blood was isolated 
from tail vein and allowed to coagulate at room temperature (RT) for 1hr prior to 
centrifugation and resuspension into 1:10 Inhibitor Solution (IS =1X HALT TM protease 
inhibitor, and 5% glycerol in 1X PBS), or collected as whole blood in vacutainer tubes 
for peripheral blood mononuclear cell (PBMC) isolation (Becton Dickinson, Franklin 
Lakes, NJ). Composite milk samples were taken aseptically after washing teat ends with 
70% ethanol. Milk was centrifuged at 700 xg for 20 min at 4°C for removal of fat, and 
skim milk was stored in 1:10 IS at -20°C prior to use in ELISA. Nasal antibodies were 
obtained by insertion of absorbant cotton into each nare and resuspension of cotton into 5 
mL of 1:10 prior to freezing at -20°C and use in ELISA. Nasal cultures were taken by 
insertion of cotton swabs into each nare (Hygiena Q-swabTM, Thermo Fisher).    
Milk Culture, PCR and Clinical Assessment 
100 L and 10 L of milk and nasal culture were plated separately on MP2 
(Udder Health Systems, Inc., Meridian, ID). The presence of small, white, esculin-
negative colonies was considered presumptive staphylococcal species. These colonies 
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were isolated and genomic DNA analyzed by PCR for confirmation of staphylococcal 
species (primers, Chapter 2, Table 2-1), as well as the S. aureus-specific gene nuc, and 
isdA and clfA. All animals were scored for the presence of clinical mastitis by 
temperature and observation of udder on days of vaccination and milk sampling 
[211,212]. SCC analysis was performed on milk using the California Mastitis Test (CMT, 
Udder Health Systems, Inc., Meridian, ID). 
IgG and IgA ELISA  
IsdA and ClfA specific immune responses on serum, milk and nasal wash were 
detected using ELISA, as described [161]. Briefly, 96-well microtiter plates (Nunc, 
Thermo Fisher) were coated with 10 g of IsdA or ClfA in 50L 1XPBS, blocked for 2 
hr at 37C in 1% goat milk + 1X PBS, and incubated with two-fold dilutions of bovine 
serum, purified milk IgG or nasal wash from Trials 1 and 2. Dilutions were initiated at a 
1:10 concentration of serum, and a 1:2 concentration of nasal wash for Trial 1, and for 
Trial 2 the total IgG concentration was determined and concentrations of serum were 
initiated at 50 g. Purified milk IgG was obtained using protein G affinity (NabTM Protein 
G and ZebaTM Spin, Thermo Fischer) and dilutions for ELISA were initiated at 25 g 
concentrations for both trials. Plates with antibody dilutions were incubated at 4°C for 12 
hr prior to washing and addition of HRP-anti-bovine IgG (1:10,000 Bethyl Laboratories, 
Montgomery, TX) or HRP-anti-bovine IgA (1:10,000 Bethyl Laboratories, Montgomery, 
TX). Samples were developed with tetramethylbenzidine (PromegaTM TMB One, Thermo 
Fisher) and read at 370 nm. Serum and milk ELISAs were performed on individual cows 
for Trial 1 (n=6-7), or pools of 6-7 cows by vaccine group for nasal wash. For Trial 2, 
ELISA results are reported using pools of 1-2 cows (n=5) for consistency with cellular 
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analysis. Data are presented as the ratio of Day Fresh (or Day X for serum)/Day1 of the 
optical density (O.D. 370 nm) from a representative antibody dilution in the linear part of 
the curve. Results are the average of three independent assays. 
PBMC Isolation, Flow Cytometry and Cytokine qPCR  
PBMCs were isolated from whole bovine blood from Trial 2 on Day 60. PBMCs 
were isolated using a density gradient established by layering whole blood diluted 1:2 
with PBS on Histopaque®1077 (Sigma-Aldrich, St. Louis, MO). Blood samples were 
centrifuged at 800 ×g for 30 min at room temperature. The buffy coat was removed and 
washed 3 X with Hank’s buffered salt solution (HBSS) for 10 min at 400 ×g at room 
temperature (RT) and counted with 0.2% Trypan blue. Mononuclear cells (PBMCs) were 
then pooled such that each pool contained cells from 2 cows in each pool (n=4-5). 
PBMCs (1 x 105) were plated in tissue-culture treated 96-well microtiter plates (Corning, 
Sigma-Aldrich) and grown in RPMI-1640 at 37 °C, 5% CO2. Cells were stimulated with 
10 µg of IsdA + ClfA endotoxin free antigen on days 1 and 3, and harvested on day 6. 
Cells were then stained with 10 µL/106 cells anti-CD4 FITC (CC8, BioRad, Hercules, 
CA) and anti-CD8 PE antibodies (CC63, BioRad), or equivalent amounts of isotype 
control (IgG2a FITC, Becton Dickenson), for 30 min in the dark at 4 °C. Samples were 
washed with 1xPBS, centrifuged at 400×g for 5 min, and resuspended in 
3% FBS/0.02% NaN3/PBS. CountBright
TM absolute counting beads (10 µL) (Thermo 
Scientific) were added to determine absolute cell numbers. Samples were analyzed for 
fluorescence intensity on a FACS Calibur flow cytometer (Becton Dickinson) and 
FlowJo data analysis software (Tree Star, Inc.). A minimum of 10,000 total lymphocyte 
events were collected for each reaction. For cytokine assays, total RNA from day 6 of 
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antigen stimulated pooled PBMCs (n=4-5) was extracted (RNeasy, Qiagen, Germantown, 
MD) with an additional DNase I (Promega, Madison, WI) digestion. cDNA was reverse 
transcribed as per manufacturer (High-Capacity RNA-to-cDNA™ Kit, Thermo Fisher). 
qRT PCR was conducted using SYBR fast (Kapa Biosystems, Thermo Fisher) on 
interferon gamma (IFN- ), interleukin-4 (IL-4) and interleukin-17 (IL-17) primers, using 
bovine GAPDH as reference gene (Table 3-1). The data are presented as fold changes 
determined by stimulated vs non-stimulated PBMC. All qRT-PCR experiments were 
performed twice using biological triplicates. 
Opsonophagocytic Assay (OPA)  
OPA was performed as described [68,213]. Briefly, equal concentrations of 
endotoxin free IsdA antigen (50 ug/well), and pooled (n=5) heat inactivated serum 
(50ug/well) or purified milk IgG antibodies (50ug/well) from days 20 and 60/Fresh of 
Trial 2 were mixed and incubated for at 37°C, 5% CO2 for 1 hour. After incubation, equal 
volumes of S. aureus Newbould 305 (2x105 CFU) and bovine PBMCs (2x105 cells) were 
added, and the reaction was further incubated for 90 minutes. PBMCs were isolated as 
described above from whole citrated bovine blood (Hardy Diagnostics, Santa Maria, CA). 
After 90 min, 10 l samples of reaction mixture were plated on MP2 in triplicate at 
1:100,000 to determine CFU/mL. Results are reported as the percent killing, or the 
reduction in CFUs/ml with serum/milk IgG compared to PBMC’s and S. aureus alone 
without serum/ milk IgG. 
Statistical Methods and Analysis  
Serum ELISA results from both trials were analyzed using repeated measures 
ANOVA on logged values in a mixed-model framework with compound symmetric 
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within-cow covariance. Vaccine groups were explicitly compared on each day with 
hypotheses not adjusted due to pre-planned comparisons. A Wilcoxon test in an exact 
testing framework was used to compare vaccine treatments for Trial 2 flow cytometry 
and qPCR data. Serum percent kill from OPA was analyzed as 3-way ANOVA (with and 
without IsdA, vaccine group, and day) and within this model vaccine group was 
compared within day and IsdA status, and IsdA status was compared within vaccine 
status. Due to the nature and number of comparisons, sets of tests were adjusted for 
multiple comparisons using the false discovery rate method [214]. Milk percent kill from 
OPA was analyzed similarly to the serum, but in a 2-way ANOVA as only milk from day 
of freshening was used. Logged humoral responses in the nasal wash were analyzed with 
a 2-way ANOVA, with vaccine groups compared within each day (not adjusted due to 
pre-planned comparisons). Logged values were used where necessary to stabilize 
variance in residual plots, and nonparametric exact methods were used with the smallest 
sample sizes and where logging did not correct the skew of the data. Statistical analyses  
were conducted using JMP (Cary, NC) and SAS software (Cary, NC). P-values are 
reported as p ≤ 0.05(*), p ≤ 0.01(**) or p ≤ 0.0001(****) and all reflect two-sided tests.  
Results 
Expression and Purification of IsdA-CTA2/B and ClfA-CTA2/B  
CT is an enterotoxin from V. cholerae which acts as a stimulatory and delivery 
mucosal adjuvant. The crystal structure of CT reveals an AB5 structure with a toxic A 
subunit and non-toxic pentameric B subunit (Figure 3-1A) [133]. To construct a mucosal 
subunit S. aureus vaccine, the toxic CTA1 domain (ctxA) was genetically replaced by 
isdA or clfA, in the parental vector pARLDR19 (Table 3-1), to form a holotoxin-like 
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CTA2/B chimera (pLR001 and pLR003, Figure 3-1B and D). IsdA-CTA2/B and ClfA-
CTA2/B chimeras were expressed in E.coli using the leader sequence LTIIB of E.coli to 
direct the secretion of IsdA-CTA2, ClfA-CTA2 and monomeric CTB to the periplasmic 
space [29]. The folded subunits were purified from the periplasm using D-galactose 
agarose affinity chromatography. The binding of CTB to the column and co-purification 
with the CTA2 fusion indicates the formation of chimeric holotoxin. The expressed 
chimeras were dialyzed, quantified and confirmed by SDS-PAGE (Figure 3-1C and 1E). 
IsdA-CTA2 (38 kD) and ClfA-CTA2 (37 kD) were co-purified with CTB (11kD). 
IsdA-HIS and ClfA-HIS were also purified from plasmids pCK001 and pMaH001 (Table 
3-1). Expression was quantified and confirmed by SDS-PAGE for the use of these 
proteins in ELISA. 
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Figure 3-1. Construction and purification of S. aureus CTA2/B chimeric mucosal 
vaccines. (A) ribbon diagram of Vibrio cholerae cholera toxin [38], (B) expression of 
the IsdA-CTA2/B chimera from E. coli + pLR001, (C) SDS-PAGE of D-galactose 
affinity-purified IsdA-CTA2/B (IsdA-CTA2 = 38kD, CTB = 11kD) vaccine 
preparation, (D) expression of the ClfA-CTA2/B chimera from E. coli + pLR003, and 
(E) SDS-PAGE of D-galactose affinity-purified ClfA-CTA2/B (ClfA-CTA2 = 37kD, 
CTB =11kD) vaccine preparation.  
Trial Design, Safety Assessment and Culture Analysis  
Two immunogenicity field trials were conducted in healthy Holstein cows during 
the dry-off period and shortly after parturition. Figure 3-2 shows the summary of trial 
design. Trial 1 group 1 (red) received 300 g intranasal doses of IsdA-CTA2/B + ClfA-
CTA2/B on days 1 and 14, group 2 (grey) was vaccinated on days 1, 14 and 49, and group 
3 (light blue) received only mock (PBS) vaccination. Trial 2 group 1 (green) received 600 
g intranasal doses of IsdA-CTA2/B + ClfA-CTA2/B on days 1 and 14 and group 2 (dark 
blue) received PBS on these days. Animals were assessed during both trials for changes 
in temperature, SCC and clinical outcome (Table 3-2), and milk/nasal wash samples were 
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cultured for the presence of Staphylococcus and genotyping of isolates (Table 3-3). No 
animals showed evidence of inflammation or clinical mastitis during either trial, and 
temperatures, as well as SCC, were not affected by vaccination. No animals in either trial 
were S. aureus positive in milk or nasal wash at any time. The presence of all 
Staphylococcus, and those specifically harboring isdA and clfA, was monitored 
throughout each trial by culture and PCR. These efforts revealed that vaccination had no 
effect on the presence and numbers of Staphylococcus in general. In addition, while a 
small number of animals were found to harbor isdA and clfA positive Staphylococcus 
prior to vaccination (4 total, Trial 2, both groups, determined to be S. hemolyticus and S. 
chromogenes), no isdA/clfA positive staphylococci was present after vaccination in any 
group in either trial. 
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Figure 3-2. Trial 1 and Trial 2 summary showing vaccination schedule, dosage, 
sample collection and number of animals Groups are: 1) Trial 1, Group 1, vaccinated 
2X on days 1 and 14 (red); 2) Trial 1, Group 2, vaccinated 3X on days 1, 14 and 49 
(grey); 3) Trial 1, Group 3, not vaccinated (light blue); 4) Trial 2, Group 1, vaccinated 
2X on days 1 and 14 (green); and 5) Trial 2, Group 2, not vaccinated (dark blue). 
 
a temperature in Fahrenheit by rectal thermometer  
b SCC in cells/mL X1000 as determined by California Mastitis Test (CMT) 
c sample taken on day of screening; -14 for Trial 1 and -9 for Trial 2.  
 
 
 
Table 3-2. Temperature and somatic cell count (SCC) from Trial 1 and Trial 2. 
 
 Trial Group Day 
Screenc 1 2 3 14 15 16 49 50 51 60 70 
Tempa 1 1 - 101.16 101.10 100.40 101.10 100.61 100.51 101.21 100.60 100.69 101.31 101.34 
2 - 100.93 101.71 100.61 101.46 100.54 100.59 101.56 100.66 100.52 101.70 101.77 
3 - 101.09 101.64 99.89 101.23 100.24 100.61 101.13 100.71 100.66 101.57 101.06 
2 1 - 100.82 98.50 98.75 99.35 - - - - - - - 
2 - 101.05 98.30 98.58 99.46 - - - - - - - 
 SCCb 1 1 49.86 - - - - - - - - - 296 851 
2 155.25 - - - - - - - - - 847.29 52.33 
3 150.86 - - - - - - - - - 126.71 132.14 
2 1 68.27 - - - - - - - - - 588.50 71.50 
2 210.55 - - - - - - - - - 1079.8 68.50 
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a percent of cows in each vaccine group positive for staphylococcal species as determined by culture and PCR. 
b Groups are defined as: Trial 1: 1=vaccinated 2X, 2=vaccinated 3X, 3=mock; and Trial 2: 1= vaccinated 2X, 2=mock. 
 
IsdA and ClfA-Specific Humoral Responses in Trials 1 and 2  
Antigen-specific humoral responses were quantified by ELISA from blood, milk 
and nasal wash collected during Trial 1, and from blood and milk collected during Trial 
2. Results are reported as a ratio of Day X/Day 1 for serum and nasal wash, and Day 
Fresh/Day 1 for milk. In Trial 1, group 2 (grey bars, Figure 3-3A), induced significantly 
higher IsdA-specific IgG responses in serum on days 60 and 70 (p = 0.027 and 0.047, 
respectively), with a consistent increase in vaccine group 1 (red bars), over unvaccinated 
group 3 (light blue bars). Anti-IsdA IgG responses from group 2 on day 49 also indicated 
an increase relative to unvaccinated group 3 (p = 0.080). Anti-ClfA responses were 
supportive of an increase in ClfA specific IgG responses from groups 1 and 2 on days 60 
and 70, but not significant (Figure 3-3B). Similarly, IsdA specific immune responses in 
milk after freshening were the highest in vaccine group 2, followed by vaccine group 1, 
Table 3-3. Culture and genotyping of Staphylococcus 
 
PCR 
primers 
Sequence Gene Amplicon Reference 
Staphylococcus: FW  GGCCGTGTTGAACGTGGTCAAATCA 
            RV  TIACCATTTCAGTACCTTCTGGTAA 
S. aureus:  FW  GCGATTGATGGTGATACGGTT  
             RV AGCCAAGCCTTGACGAACTAAAGC 
isdA:  FW  CGGTTCAACCAAAACCTGCT 
           RV   GCGAAGGCAACTGTGCTAAT 
clfA:   FW  CCTATGCCAGTAGCCAATGTC  
           RV   GCACCAAGCAGGTTATGTC  
tstaG 
 
nuc 
 
isdA 
 
clfA 
 
370 bp 
 
270 bp 
 
380 bp 
 
318 bp 
[83] 
 
[84] 
 
[68] 
 
[68] 
Percent 
Staph 
positivea 
Trial Sample Group Day 
Screenb 1 14 49 60 70 
1 
 
nose 1  - 0 57 14 14 29 
2  - 29 57 0 50 17 
3  - 0 14 29 43 43 
milk 1 14 - - - - 0 
2 29 - - - - 17 
3 29 - - - - 14 
2 
 
milk 1 9 - - - - 22 
2 27 - - - - 40 
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relative to unvaccinated group 3, but not significant (Figure 3-3C). Anti-ClfA responses 
in milk were more variable, but with a lower ratio in the unvaccinated group compared to 
both vaccinated groups (Figure 3-3D). In Trial 2, the vaccinated group 1 (green bars, 
Figure 3-4A) showed a significant increase in the IsdA-specific IgG immune responses 
over unvaccinated group 2 (dark blue bars) in serum on days 20 and 49 (p = 0.009 and 
0.0003, respectively), and a supportive increase on day 60. Anti-ClfA responses in serum 
were consistent with anti-IsdA responses, but were significant on day 20 only (p = 0.013) 
(Figure 3-4B). IsdA-specific IgG responses in milk upon freshening were also higher for 
the vaccinated group in this trial, but not significant (Figure 3- 4C). Lastly, the ClfA 
antigen did not stimulate detectable IgG immune responses in milk over unvaccinated 
(Figure 3-4D). Nasal wash anti-IsdA IgA was also assessed from pooled samples 
obtained in Trial 1, and results are supportive of a stimulation of antigen-specific IgA, 
especially within group 2 (Figure 3-5 grey bars, group 2 showing higher response than 
group 3 on day 70 only, p = 0.043). Together, results demonstrate that antigen-specific 
humoral responses can be stimulated after intranasal vaccination with IsdA-CTA2/B + 
ClfA-CTA2/B. 
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Figure 3-3. Trial 1 humoral responses in serum and milk. Anti- IsdA (A) and anti-
ClfA (B) IgG responses as determined by ELISA using serum from days 14, 49, 60 
and 70. Results are reported as ratios of Day X/Day (O.D.) at serum dilution of 1:320. 
Anti-IsdA (C) and anti-ClfA (D) IgG responses as determined by ELISA using IgG 
purified from milk on day 60 or 70 (Day Fresh). Results are reported as ratios of Day 
Fresh/Day 1 (O.D.) at IgG dilution of 1:80 (3.125 g). Groups are: 1) vaccinated 2X 
on days 1 and 14 (red), 2) vaccinated 3X on days 1, 14 and 49 (grey), and 3) not 
vaccinated (light blue). Data are presented as the mean ± standard error for serum 
(n=6-7), or quartile box plots with medians for milk (n=6). Significance (*) on Day 60 
and Day 70 (p = 0.027 and p = 0.047) is shown. 
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Figure 3-4. Trial 2 humoral responses in serum and milk. Anti- IsdA (A) and anti-
ClfA (B) IgG responses as determined by ELISA using serum from days 7, 14, 20, 49, 
60 and 70. Results are reported as ratios of Day X/Day 1 (O.D.) at serum dilutions of 
1:1280 (400 ng total protein). Anti-IsdA (C) and anti-ClfA (D) IgG responses as 
determined by ELISA using IgG purified from milk on day 60 or 70 (Day Fresh). 
Results are reported as ratios Day Fresh/Day 1 (O.D.) at milk dilution of 1:80 (3.125 
g). Groups are: 1) vaccinated 2X on days 1 and 14 (green), 2) not vaccinated (dark 
blue). Data are presented as the mean ± standard error for serum or quartile box 
plots with medians for milk (n=5). Significance (**) on Days 20 and 49 for anti-IsdA 
responses (p = 0.009 and p = 0.0003) and (*) on Day 20 for anti-ClfA response (p = 
0.013) is shown. 
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Figure 3-5. Trial 1 humoral responses in nasal wash. Anti-IsdA IgA responses in 
pooled nasal wash on days 14, 49, 60 and 70. Results are reported as ratios of Day 
X/Day1 (O.D.) at a nasal wash dilution of 1:16. Groups are:1) vaccinated 2X on days 
1 and 14 (red), 2) vaccinated 3X on days 1, 14 and 49 (grey) and 3) not vaccinated 
(light blue). Data are presented mean ± standard error (n=3); significant difference 
between vaccine groups 2 and 3 on day 70 (*, p = 0.043) is shown. 
Induction of Cellular Immune Responses from Trial 2 
The stimulation of T cell responses was assessed after the isolation of PBMCs 
from cows on day 60 of Trial 2, and the stimulation of these cells in vitro with purified 
IsdA+ ClfA antigen. Flow cytometry was used to determine concentrations of CD8+ and 
CD4+ cells in stimulated and unstimulated groups (Figure 3-6A). Cows vaccinated with 
IsdA-CTA2/B and ClfA-CTA2/B on day 60, show a significant increase in the 
proliferation of CD4+ T cells after stimulation compared to the non-vaccinated control 
group (p = 0.032; Figure 3-6B). The vaccinated group also revealed a modest increase in 
the proliferation of CD8+ T cells. The levels of IFN-γ, IL-4 and IL-17 cytokine 
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expression was also assessed by qRT-PCR from antigen (IsdA + ClfA) stimulated 
PBMCs on day 60. PBMCs from cows immunized with IsdA-CTA2/B + ClfA-CTA2/B 
revealed significantly higher expression levels of IL-4 upon stimulation (p = 0.016), but 
no detectable increase in INF-γ or IL-17 (Figure 3-6C). These results indicate that the 
mucosal immunization with IsdA-CTA2/B and ClfA-CTA2/B stimulated a Th2-type 
cellular response. 
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Figure 3-6. Trial 2 cellular and cytokine responses. Flow cytometric analysis to 
determine proliferation of CD4+ and CD8+ T-lymphocytes from Day 60 after 
stimulation with IsdA + ClfA: (A) representative light scatter dot plots showing the 
gated bead and lymphocyte populations for unstimulated and stimulated PBMCs, as 
well as the lymphocyte gated population of CD8-PE vs CD4-FITC, where the CD8 
population falls in quadrant 3 (Q3) and CD4-FITC population in quadrant Q4, and 
(B) quantification of flow cytometry showing the CD4+ T cell and CD8+ T cell 
stimulation index in vaccinated (green) and unvaccinated (blue) groups. Significance 
(*) for CD4+T cell stimulation is. (C) Quantitative RT-PCR to determine cytokine 
expression from Day 60 antigen-stimulated PBMCs isolated from vaccinated (green) 
and unvaccinated (dark blue) cows, showing: IL-4, INF- and IL-17 expression. Data 
is reported as normalized Ct values fold change over GAPDH. Significance (*) for 
CD4+ T cell (p = 0.032) and IL-4 expression (p = 0.016) is shown. 
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Opsonophagocytic Activity of Isda Specific IgG Antibodies from Trial 2  
The in vitro activity of antibodies stimulated against IsdA was assessed by OPA 
using serum and milk from days 20, 60 and fresh of Trial 2 (Figure 3-7). Serum from 
days 20 and 60 of vaccinated cows showed a significant increase in killing activity in the 
absence of purified IsdA (p < 0.0001 and p = 0.009, respectively). When purified IsdA 
was added to the assay, percent killing was reduced in the vaccinated group on both days 
(p < 0.0001 and p = 0.001 for days 20 and 60, respectively) (Figure 3-7A and B). Purified 
IgG from the milk of vaccinated cows upon freshening also showed significant 
opsonophagocytosis activity in the vaccinated group relative to the unvaccinated group (p 
= 0.041), and consistent blocking of killing activity in the presence of IsdA antigen in the 
vaccinated group (p = 0.010) (Figure 3-6C). Overall results of this assay indicate that, 
antibodies stimulated against IsdA are active against isogenic S. aureus in vitro and 
induce significant opsonophagocytic responses.  
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Figure 3-7. In vitro activity of anti-IsdA responses from Trial 2 serum and milk. 
Opsonophagocytic assay (OSP) to determine the ability of anti-IsdA humoral 
responses from days 20 (A) and 60 (B), or pooled milk from day Fresh (C), of 
vaccinated (green) and unvaccinated (dark blue) cows, to promote phagocytic killing. 
Samples were also pre-mixed with (+IsdA) or without (-IsdA) purified IsdA to assess 
the inhibition of serum activity. Results are reported as percent killing (CFU/mL) of 
S. aureus Newbould 305 by bovine PBMCs after mixture with pooled serum 
compared to a control of PBMCs plus S. aureus in the absence of serum (n=5). P-
values are adjusted for false discovery rate [214]. Significance between serum in 
vaccine groups without IsdA on days 20 and 60 is shown (p = < 0.0001 *** and p = 
0.009 ** respectively); as is significance between IsdA presence and absence on days 
20 and 60 (***, p < 0.0001 both days); in milk, vaccine groups differ (p = 0.041) and 
in the vaccinated group, percent killing differs by IsdA status (p = 0.01,* shown). 
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Discussion 
Bovine mastitis is one of the most important diseases of the dairy industry and 
developing methods of prevention is a top priority. New approaches that can induce 
complex responses to block colonization and transmission are needed. In this study, we 
describe the results of two clinical trials using a mucosal subunit vaccine (IsdA-CTA2/B + 
ClfA-CTA2/B) against S. aureus caused bovine mastitis. Both trials were conducted at the 
start of the lactation dry period, vaccine was administered intranasally and boosted either 
one or two times during the trial. Blood and milk samples were collected during and at the 
end of the trial to detect immune responses. Significant antigen-specific immune responses 
were detected in the serum of vaccinated animals in both the trials. In Trial 2, cytokine 
expression profile revealed that vaccine induced immune responses were largely Th2-type. 
Importantly, the antibodies that were stimulated were specific to IsdA, active and effective 
in triggering opsonophagocytosis in vitro. The IsdA-CTA2/B + ClfA-CTA2/B vaccine was 
found to be safe and well tolerated intranasally, at dosage as high as 1200 µg.  
IsdA is a FN and FG binding surface adhesin from S. aureus, it also contributes to 
iron sequestration, surface hydrophobicity and lactoferrin resistance. Multiple reports have 
described IsdA as a central human antigenic vaccine target [62,64,161]. ClfA is an FN 
adhesin, also known to be conserved and immunogenic [124,195,209]. As described in 
Chapter 1, ECM binding is critical for colonization of S. aureus in the cow udder, as this 
interaction potentiates its uptake intracellularly into various cells like, macrophages, 
neutrophils, mammary gland epithelial cells (MacTs) [215,216]. 
Our results from both the trails indicated that there is an antigen-specific increase 
in humoral immune responses in vaccinated animals. Both IsdA and ClfA stimulated 
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immune responses, however, immune responses stimulated against IsdA were consistently 
higher in both trials, as compared to ClfA. This may be due to the structure and differential 
stability of IsdA-CTA2/B compared to ClfA-CTA2/B. The antigenic surfaces exposed 
during folding of chimera could facilitate higher antibody stimulation with more specificity 
for IsdA [217,218]. Also, antigens combined with CTA2/B chimeras can potentially lose 
their tertiary structure, which is a limitation that can influence antibody stimulation and 
specificity [219]. The results from OPA indicated that anti-IsdA antibodies were induced 
and were responsible for the majority of the in vitro killing activity of S. aureus. These 
results indicate that, while anti-IsdA responses were induced to a higher level, addition of 
ClfA was beneficial, and this antigen may have contributed to cellular responses. Future 
incorporation of additional antigens will be essential to optimize efficacy. 
Successful prevention by vaccine relies on the timing of vaccination and booster 
doses thereafter. In Trial 1, there were two vaccinated groups and one unvaccinated. The 
group that was vaccinated twice (1) was compared to group 2 vaccinated three times and 
the unvaccinated group. There was a slight but supportive booster effect seen after the third 
dose of vaccination in group 2 In Trial 2, the vaccination was administered at a higher dose, 
which induced higher immune responses in serum over the 50-day period of vaccination 
with a more distinct booster effect, however these responses declined sharply during the 
freshening period. Despite this drop, anti-IsdA IgG antibodies in milk were consistently 
elevated in vaccinated animals upon freshening. Importantly, milk antibodies from this 
trial, in which cows had received the last booster on day 14, were active and effective in 
OPA despite having lower serum responses. Opsonophagocytosis, or the demonstration of 
functional antibody activity, has been described as critical for a successful S. aureus 
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vaccine [220]. Here we revealed that the opsonophagocytic antibodies stimulated from 
both serum and milk during freshening were highly significant, antigen-specific, and 
supportive of their protective capacity. 
Another key feature required for the success of a subunit vaccine is an adjuvant. 
Adjuvants are important for targeted delivery, antigen presentation and stability of the 
vaccine. CT, is a gold standard mucosal vaccine adjuvant that has been used extensively in 
animal studies [221–223]. CT has been reported to have anti-inflammatory properties 
[224,225]. CTA2/B is a genetically engineered CT chimera that was first described as a 
mechanism to make stable human vaccines with the antigen directly coupled to a functional 
CTB subunit [226–229]. CTA2/B chimeras have advantages over CT for use as mucosal 
vaccines, including: the absence of the toxic A1 domain, the non-covalent association of 
antigen and adjuvant, and a native receptor-binding subunit that retains the A2 ER-targeting 
KDEL motif [136]. Evidence suggests that an A2/B chimeric structure may promote 
antigen uptake and presentation, resulting in efficacy in animal models [170,171,230]. Our 
results support the use of CTA2/B chimeras for bovine vaccination, and suggest that 
intranasal vaccination with CTA2/B can induce antigen-specific antibody production at the 
mucosal surface and in milk.  
Despite decades of research, S. aureus has proven to be a difficult pathogen to 
eliminate. The development of an effective vaccine to prevent bovine mastitis caused by S. 
aureus would reduce bovine morbidity and mortality, increase food production and quality, 
reduce antibiotic use and potentially inform human vaccine development. This report 
describes the novel approach that may address these needs. Results are supportive of the 
continued assessment of CTA2/B chimeras as bovine vaccines to prevent S. aureus mastitis.  
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CHAPTER FOUR: IMMUNOPROTEOMICS TO IDENTIFY STAPHYLOCOCCUS 
AUREUS ANTIGENS EXPRESSED IN BOVINE MILK DURING MASTITIS 
 
Abstract 
      Staphylococcus aureus is an opportunistic pathogen affecting both human and animal 
species. An effective vaccine to prevent S. aureus bovine disease and transmission would 
have positive impacts on animal well-being, food production and human health. The 
objective of this study was to identify multiple immunogenic antigens that are involved in 
udder colonization and disease for incorporation into a vaccine to prevent bovine 
mastitis. S. aureus produces a number of cell wall anchored and surface-associated 
virulence factors that play key roles in the pathogenesis of mastitis. Many of these 
proteins are conserved between different strains and serotypes of S. aureus, and represent 
promising vaccine candidates. In this study, we utilized an immunoproteomics approach 
to identify antigenic proteins from the surface of S. aureus. The expression of cell wall 
and surface proteins from S. aureus was induced under low iron conditions, followed by 
trypsin extraction and separation by two-dimensional electrophoresis (2DE). The 
separated proteins were blotted with antibodies from mastitic bovine milk, and identified 
by liquid chromatography-mass spectrometry (LC/MS/MS) analysis. Thirty-eight unique 
proteins were identified, of which eight were previously reported to be involved in S. 
aureus virulence. Two immunogenic surface proteins; IsdC and EsxA, were cloned, 
expressed, and purified from E.coli for confirmation of immune reactivity by ELISA. 
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Amino acid alignments of published S. aureus sequences indicated that IsdC and EsxA 
are highly conserved. PCR on 37 bovine S. aureus isolates determined that the presence 
of esxA and isdC is also conserved. The immunoproteomics technique used in this study 
generated reproducible results and identified at least two promising vaccine antigens for 
use in novel vaccines to prevent bovine mastitis. 
Introduction 
     Bovine mastitis is an important and economically relevant disease that affects the 
dairy industry worldwide [175,231]. This disease causes large economic losses every 
year; estimated to be as high as $2 billion/year in the U.S. alone [15,232]. These losses 
are mainly due to reduced milk yield, antibiotic therapy, veterinary services and the 
reduced price of culled animals [178,233]. Mastitis is most often an acute or chronic 
inflammation of mammary glands caused by bacterial infection, and commonly leads to 
increased somatic cell count (SCC), cytokine production, antibody secretion and bacterial 
load in milk [105,234]. Multiple pathogens are known to cause bovine mastitis, however, 
S. aureus is one of the most commonly isolated pathogens in milk, and an estimated 3% 
of dairy cows worldwide are infected [235]. S. aureus infection often results in chronic, 
subclinical disease that is highly contagious, and difficult or impossible to treat, with cure 
rates lower than 25% [236] . Despite decades of research, an effective vaccine that can 
prevent S. aureus bovine disease is not yet available; largely due to strain to strain 
variability and redundancy of S. aureus virulence factors. The strategy to design effective 
vaccines for S. aureus mastitis must include multiple conserved and immunogenic 
virulence factors that can provide cross-protection for the many strains of this bacterium. 
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S. aureus expresses a broad range of virulence factors, that include surface 
proteins covalently attached to the cell wall and secreted proteins expressed during 
infection [237]. These exposed proteins are essential for the survival and proliferation of 
S. aureus, and the presence of many of them is conserved  [238,239]. Depending upon 
the stage of infection and physiological conditions inside the host, virulence factor 
expression will promote binding to the extracellular matrix (ECM), colonization, 
invasion, and avoidance of the immune response [240]. A number of these factors have 
been emphasized in both human and veterinary vaccines as important targets effective for 
vaccine development [201]. The iron-regulated surface protein A (IsdA) is an S. aureus 
surface adhesin that is also involved in iron sequestration and found to be highly 
expressed, conserved and immunogenic during in bovine mastitis [184]. Other adhesins, 
such as: IsdB, ClfA and HlA, also have antigenic properties in models for human S. 
aureus infection, however, their role in bovine disease requires further exploration 
[68,241]. 
Proteomics is an important tool to identify potential vaccine antigens, especially 
for pathogens like S. aureus with numerous surface exposed proteins [242,243]. Studies 
have reported the use of two-dimensional electrophoresis (2DE) for whole or subcellular 
proteome analysis of S. aureus for human vaccine development [244]. Couto et al. 
(2016), recently described the use of the SERPA (serome proteome analysis) technique to 
explore and characterize novel vaccine and therapeutic targets for S. pseudointermedius 
infections in dogs [245]. Mastitic cow milk specifically contains neutrophils, 
lymphocytes and antibodies as a result of infection and subsequent inflammation [92]. 
Immune cells, secreted antibodies and cytokines present in milk during S. aureus acute or 
84 
 
 
 
chronic infection are important tools to identify bacterial antigens relevant to disease. 
Immunoproteomics utilizes a combination of proteomics and immunoblotting to identify 
antigenic proteins and factors. SERPA combined with immunoproteomics has been 
employed to identify antigenic proteins using serum from infected cows with subclinical 
mastitis [246,247]. In addition, various bioinformatics tools, such as reverse vaccinology 
and in-silico approaches, have also been explored to analyze the surface proteome of S. 
aureus with a focus on vaccine antigenic targets [26,248,249]. Important contributions 
have been made using these techniques, however more immunologically extensive and 
disease-, as well as host-, specific approaches are needed for an effective S. aureus 
vaccine against bovine mastitis. 
In this study, our aim was to use mastitic milk antibodies to identify relevant 
antigens for the prevention of bovine mastitis. Here we report that 2DE, coupled with 
immunoblotting and mass spectrometry, promoted the identification of immunogenic 
vaccine candidates from S. aureus. We characterized and prioritized these candidates in 
silico, and cloned and purified the antigens, EsxA and IsdC. EsxA and IsdC were 
confirmed by ELISA to be immunogenic and surface exposed during S. aureus infection 
of the udder. In addition, sequence analysis and PCR on genomic S. aureus DNA 
indicated that EsxA and IsdC were conserved and the presence of these antigens is found 
on the majority of bovine isolates. This is the first known report of the use of 
immunoproteomics to identify S. aureus antigens using milk from cows with mastitis.  
 
 
 
85 
 
 
 
Materials and Methods 
Bacterial Strains, Culture Conditions and Milk Samples  
     The S. aureus strains used in this study were Newbould 305 [208], a clinical strain 
(C1, kindly donated by M. McGuire) and 37 additional clinical bovine S. aureus isolates 
(kindly supplied by Udder Health Systems Inc, Meridian, ID). Bovine S. aureus was 
characterized and confirmed by growth and haemolysis on MP2 agar (Udder Health 
Systems, Inc.), coagulase production, and 16s rRNA sequencing. For genomic DNA 
isolation, S. aureus was grown in Luria Broth (LB) with shaking at 37C. For cell wall 
protein and surface adhesin expression,  S. aureus was grown in low iron media (LIM) 
[250] with shaking at 37°C. For use in 2DE, milk from four different clinically mastitic 
cows was obtained from a diagnostic laboratory after confirmation of the presence of S. 
aureus by mass spectrometry (MALDI, Udder Health Systems Inc., Meridian, ID). Milk 
was pooled and 10 and 100l was plated on MP2 agar for CFU determination (1.7x107 
CFU/ml), S. aureus isolation, and confirmation as described above. Commercially 
available pasteurized milk, and pooled unpasteurized milk obtained from 5 S. aureus 
negative cows, was used as negative milk for comparison in 2DE. Unpasteurized milk 
obtained from five S. aureus infected cows and five S. aureus uninfected cows was used 
for ELISA. Collection and processing of milk for ELISA and negative control milk is 
described previously [184].  
Isolation of S. aureus Cell Wall Associated Proteins  
Cell wall associated proteins were isolated using trypsinization as reported [21]. 
Briefly, S. aureus Newbould 305, S. aureus C1, and E.coli (DH10- Top10, Thermo 
Fisher) were grown in LIM overnight to an O.D. of 0.75-1.2 and harvested by 
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centrifugation (6000 ×g for 10 min at 4°C), prior to washing three times with 1x PBS 
(Table 1). Cells were then resuspended in 1/50 volume of the original culture in1x PBS 
containing 40% sucrose (pH 7.4) for 5 mins. Digestion was carried out with the addition 
of 50 μg of trypsin plus 2 mM DTT for 1hr at 37°C. The digested mixture was 
centrifuged at 3500 ×g for 10 min, and the supernatant with peptides was filtered with a 
0.22 μm filter. Protease reactions were stopped with protease inhibitor solution (Halt 
Protease Inhibitor Cocktail 100X, Thermo Fisher Scientific, Waltham, MA). Total 
protein was analyzed by SDS-PAGE and measured for concentration using BCA (Pierce 
BCA protein assay kit, Thermo Fisher). 
 
 
Table 4-1. Bacterial strains, plasmids and primers used in this study. 
Bacterial strains 
 Genotype/relevant information Reference or source 
 S. aureus Newbould 305   Bovine clinical isolate   [208] 
 S. aureus Clinical    Bovine clinical isolate This study 
 E.coli Top10   DH10 Invitrogen (Thermo Fisher) 
Plasmids 
  Gene Vector Reference or source 
 pNM002 
pNM003 
esxA (Newbould 305) 
isdC (Newbould 305) 
pTRCHisA 
pTRCHisA 
This study 
This study 
Primers 
PCR                                                                                                                                  Amplicon (bp)      Source 
esxA: FWGGCAATGATTAAGATGAGTCC                                                                                      287                  This study 
          RVGCAAACCGAAATTATTAG 
isdC   FWGAGTATCGAAGGACATAAAG                                                                                        384                  This study 
          RVGCTAAGGATGCAACTGG 
Clones 
pNM002:      
        FWGCTTCCGGGATCCGCAATGATTAAGATGAGTCCAG                    
        RVCAGTGCGGAATTCTTATTGCAAACCGAAATTATTAG  
pNM003:      
        FWGCTTCCGGGATCCGCAGATAGCGGTACTTTGAATTATG  
        RVCAGTGCGAAGCTTTTATTCCACATTGCCTTTAG 
pCK001:     
        FWGCTACTGGATCCGCGGCAACAGAAGCTACGAAC                    
        RVGTGCATAAGCTTTCAAGTTTTTGGTAATTCTTTAGC             
 Gene  Amplicon 
(bp) 
Source 
 
esxA                 
 
 
isdC 
 
 
isdA 
 
         
      297 
                          
          
         606 
 
          
         852 
 
 
This study 
 
 
This study 
 
 
[65] 
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Two-Dimensional Gel Electrophoresis (2DE) and Western Blotting  
Trypsinized protein extracts were cleaned using the ReadyPrep 2-D Cleanup kit 
(Bio-Rad, Hercules, CA) following manufacturer’s instructions, and resuspended in 
ReadyPrep rehydration buffer. A total of 150 lof 165 g/ml of protein was used to 
rehydrate a 7 cm immobilized pH gradient (IPG) strip (Bio-Rad, Hercules, CA), pH 4-7 
for 24 hrs. Rehydrated IPG strips were then iso-electro focused (IEF) on the first 
dimension using the Protean IEF system (Bio-Rad) at cycles 250 voltage for 20 min 
linear followed by 4000 volts for 120 min and 4000 volts at 10,000V-hr rapid. After IEF 
strips were equilibrated using equilibration solution I and II (2-D Starter kit, Bio-Rad) for 
15 min each. For second dimension separation, the equilibrated strips were run on 12% 
SDS-PAGE and stained with Coomassie blue. 2D gels were electro-transferred to a 
polyvinylidene difluoride (PVD) membrane and blocked using blocking buffer (0.05% 
Tween 20 + 5% skim milk + 1× PBS). Membranes were washed and blotted with pooled 
mastitic milk or S. aureus negative milk (1:5000, dilution). The membrane was 
developed using the ECL western blotting substrate (Pierce, Thermo Fisher) and exposed 
to film for 24 hours to detect chemiluminescence.  
Reported data represent 5 independent blots performed using pooled mastitic milk 
on separated proteins from S. aureus Newbould 305. Additional blots for comparison 
were performed each at least twice, using: 1) uninfected pasteurized milk on proteins 
from Newbould 305, 2) pooled unpasteurized milk from 5 S. aureus negative cows on 
proteins from Newbould 305, 3) pooled mastitic milk on trypsinized proteins from E.coli, 
and 4) pooled mastitic milk on trypsinized proteins from S. aureus C1. Spots identified 
on the western blot film were compared and aligned to the Coomassie blue stained 2D gel 
88 
 
 
 
using ImageJ software (https://imagej.nih.gov/ij/ ) to enable the selection of proteins with 
the brightest spot. Only those proteins showing prominent bright spots on S. aureus 
Newbould 305 or C1 immunoblots using S. aureus infected milk were picked for 
identification by mass spectrometry.  
Mass Spectrometry Analysis  
The proteins aligned with the brightest spots on the western were picked using a 
spot picker and digested with trypsin as described with modifications [245]. Briefly, gel 
spots were destained in buffer (50 mM ammonium bicarbonate/50% acetonitrile, reduced 
in 10 mM DTT) for 60 min at 56oC, and alkylated in 55 mM iodoacetamide for 60 min at 
room temperature (RT) in the dark. Proteins were then digested with 20 µg/ml trypsin 
overnight at 30oC. Peptides were extracted from the gel, dried under vacuum, and 
reconstituted in buffer (5% acetonitrile, 0.1% formic acid in water) for LC-ESI-MS/MS 
analysis. 5 L of peptide mixture was injected onto a C18 reverse-phase column (10 cm x 
75 µm, 3 µm, 120 Å). A linear gradient with two mobile phases at a flow rate of 300 
nL/min was used to separate peptide mixtures. Full scan MS spectra were acquired from 
m/z 300-2000.  
Collision-induced dissociation (CID) was used to fragment the precursor ions. 
MS/MS spectra were acquired in the data-dependent acquisition mode for the top ten 
most abundant precursor ions in the preceding full MS scan. Peptide spectral matching 
and protein identification were achieved by database search using Sequest HT and 
Mascot algorithms in Proteome Discoverer 1.4 (Thermo Scientific, Waltham, MA, USA). 
Raw spectrum data were searched against the UniProtKB/Swiss-Prot protein database for 
S.aureus (www.uniprot.org/ , obtained on June 14, 2016). Immunogenic proteins were 
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ranked on the basis of location and function using the PSORTb v3.0.2 
(www.psort.org/psortb/) and UniProt (www.uniprot.org), and adhesion potential using 
Vaxign (www.violinet.org/vaxign/) (Table 2 and Supplementary Table 1). 
Pcr, Cloning and Purification of Recombinant Proteins  
Gene presence/absence was determined by electrophoresis of PCR products 
performed three times under optimized conditions. Primer an amplicon sizes are as 
indicated (Table 1). The plasmids; pNM002 and pNM003 were constructed for the 
expression of His-EsxA and His-IsdC. Corresponding primers for isdC and esxA (Table 
1, restriction sites underlined) were used to PCR amplify genomic DNA from S. aureus 
Newbould 305. The resulting product was cloned into pTrisHisA (Invitrogen, Carlsbad, 
CA) and plasmids were transformed into E.coli Top10 (Thermo Fisher). Plasmids were 
confirmed by sequencing through the junctions. Transformed cells were induced and 
proteins were isolated from the bacterial cytosol for purification by cobalt affinity 
chromatography (Talon Metal Affinity Resin; Clontech Laboratories, Mountain View, 
CA) under denaturing conditions. Purified proteins were dialyzed against phosphate-
buffered saline (1x PBS) with 5% glycerol, analyzed by SDS-PAGE, and confirmed by 
mass spectrometry. Protein concentrations were determined by BCA as described above.  
ELISA  
ELISA was used to detect antigen-specific antibody responses in milk from five 
S. aureus infected cows and compared to five uninfected controls. Microtiter plates 
(Nunc, Rochester, NY) were coated with 10 g of purified protein (EsxA and IsdC, 
described above) per well in 1x PBS, blocked with buffer (1% skim milk + 1x PBS), and 
incubated with 2-fold dilutions of bovine milk, starting at 1:10 dilution, for 12 hr at 4°C. 
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Plates were then  washed with PBS-T (1× PBS + 0.05% Tween 20), incubated with HRP-
conjugated anti-bovine IgG (1:10,000; Thermo Scientific, Rockford, IL) in blocking 
buffer for 1 hr at 37°C, washed again and developed with tetramethylbenzidine (TMB 
One, Promega, Madison, WI). IgG titers were calculated after background values 
(protocol minus samples) were subtracted. Endpoint titers were defined as the reciprocal 
of the dilution giving an OD of 0.2, and results are representative of the assay performed 
independently three times. 
Data and Statistical Analysis  
Graphing and statistical analysis was performed with JMP SAS software (Cary, 
NC). Significance for ELISA was assessed using two-tailed Student’s t-test for unequal 
variance. Values are reported as p ≤ 0.05(*). Decoy database search was performed to 
calculate false discovery rate (FDR) of mass spectrometry data. Proteins containing one 
or more peptides with FDR≤0.05 were considered positively identified and reported. 
Results 
Extraction of Cell Wall Associated Proteins  
The S. aureus surface proteome was used as the target for immunoproteomics in 
this study. Figure 4-1 illustrates the method of preparation of protein samples used to 
promote reliable identification of immunogenic surface or cell-wall bound proteins. S. 
aureus was cultured in low iron media (LIM) for the induction of virulence-related 
surface/cell wall anchored proteins and collected during late exponential and early 
stationary phase. Cells were trypsinized to release the cleaved surface fraction and 
separated in the first dimension by iso-electro focusing (IEF). After second-dimension 
separation, immunoproteomic analysis was conducted by performing a western blot on 
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the 2DE gel using S. aureus infected pooled milk. The goal of these methods was to 
detect surface exposed S. aureus proteins that induced humoral responses in the mastitic 
milk of infected cows.  
 
 
92 
 
 
 
Figure 4-1. Diagram of the immunoproteomics techniques used for detection of 
immunogenic surface proteins from S. aureus. The experimental workflow, including: 
2DE, immunoblots and mass spectrometry analysis, for identifying bovine disease 
relevant antigens is shown.  
Identification of Immunogenic Antigens  
S. aureus Newbould 305, an S. aureus bovine clinical isolate, and E. coli (DH10-
) surface proteins were trypsinized and extracted and first run in one dimension on SDS-
PAGE (Figure 4-2A, lanes 1 and 2). The isolated proteins were then rehydrated and 
separated on a two-dimensional gel, as shown in Figure 4-2B and D. In order to assess 
the immunogenic proteins from S. aureus as previously mentioned, trypsinized proteins 
were subjected to western blot. To limit the selection of cross-reactive proteins, E.coli 
surface proteins were also extracted and subjected to western blot analysis using mastitic 
cow milk as a negative control. As expected, mastitic milk recognized more proteins 
from the S. aureus extract (Figure 4-2C). Several highly immunogenic areas (containing 
multiple spots) were detected only in S. aureus blots and not in the E. coli blot (Figure 4-
2C and E). Very few immunogenic proteins were detected in the control milk western 
blots. The anti-staphylococcal antibody repertoires from mastitic cows were deemed to be 
unique and a relevant tool for further analysis. 
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Figure 4-2. Representative SDS-PAGE, 2DE and western blots showing the 
workflow to the selection of immunogenic spots (A) The 1-dimensional SDS-PAGE 
image of S. aureus Newbould 305 trypsinized protein (lane 1) and E. coli trypsinized 
protein (lane 2). (B) 2DE gel conducted on 7 cm, pH 4-7, IPG strips on S. aureus 
trypsinized protein. (C) Immunoblot of S. aureus 2DE using pooled bovine mastitic 
milk, with the immunogenic region highlighted in red circles. (D) 2DE gel conducted 
on 7 cm, pH 4-7, IPG strips on E. coli trypsinized protein. (E) Immunoblot of E. coli 
2DE using bovine mastitic milk, with the immunogenic areas of the blot highlighted 
in red circles. 
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LC-MS/MS and in silico Analysis  
2DE was performed five times, using trypsinized proteins from Newbould 305, a 
clinical bovine mastitis S. aureus isolate and E. coli. The collected immunogenic spots 
corresponding to western blots were picked and identified by tandem mass spectrometry. 
An uninterpreted database search approach using Sequest and Mascot algorithms was 
employed to identify peptides and proteins. The complete set of identified proteins using 
this approach is listed in Table 4-4 and ranked by coverage, location and function. The 
most promising immunogenic proteins for incorporation into a bovine vaccine were 
further ranked on the basis of location and function using the PSORTb, UniProt and 
Vaxign online tools (Table 4-2) [251–253]. Two specific surface exposed proteins and 
virulence factors, IsdC and EsxA, were targeted for further characterization. Figure 4-3 
shows a representative peptide spectral match of the isolated IsdC and EsxA 2DE 
peptides. 
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Table 4-2. Selected antigens on the basis of coverage, function, adhesion probability 
and location. 
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Figure 4-3. Representative MS/MS spectra of peptides identified by Mascot. (A) 
MS/MS fragmentation of AQGEIAANWEGQAFSR found in the ESAT-6 secretion 
system extracellular protein (EsxA); (B) MS/MS fragmentation of 
FNGPTDVAGANAPGKDDK found in the Iron-regulated surface determinant 
protein C (IsdC). 
Conservation and Prevalence of Antigens  
To determine if IsdC and EsxA are conserved at the amino acid level, 
phylogenetic analysis was completed using 50 published sequences 
(www.ncbi.nlm.nih.gov) as shown in Figure 4-4. Results include five known cow isolates 
and percent identity is compared to S. aureus Newbould 305. Sequences of both proteins 
are highly conserved, with EsxA 100 % conserved among S. aureus. PCR was performed 
to estimate the genetic prevalence of isdC and esxA in bovine isolates of S. aureus. Gene-
specific primers (Table 4-1) were used to amplify the genes from 37 clinical bovine S. 
aureus isolates and compared previously reported analysis of isdA [184]. As shown in  
 
97 
 
 
 
 
Table 4-3, The results indicate that the presence of isdC and esxA is 92% conserved 
in bovine S. aureus isolates. 
 
 
 
Figure 4-4. Dendrogram of pairwise amino acid alignments of (A) IsdC and (B) 
EsxA from 50 published sequences. Evolutionary analysis was performed with the 
Maximum Likelihood method based on the JTT matrix-based model (MEGA, 
Version 7). Percent identity to the sequence from the bovine Newbould 305 S. aureus 
strain is shown. Isolates from cow (*) are indicated 
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Cloning, Expression and Immunogenicity of Antigens  
isdC and esxA were cloned into a 6X histidine vector to construct the expression 
plasmids, pNM003 and pNM002 (Figure 4-5A and C). IsdC (~25.5 kD) and EsxA (~14.5 
kD) proteins were then expressed and analyzed on SDS-PAGE (Figure 4-5B and D). 
Purified proteins were then used to confirm the immunogenicity of IsdC (Figure 4-6B) 
and EsxA (Figure 4-6C) by ELISA using S. aureus culture positive or negative milk from 
5 different cows. Immune responses to the previously characterized IsdA were also 
determined for comparison (Figure 4-6A) [184]. IsdC and EsxA were found to stimulate 
significant IgG antibody titers in mastitic milk as compared to uninfected milk. Results 
indicate that IsdC and EsxA are immunogenic and expressed in vivo in the bovine udder. 
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Figure 4-5. Expression and purification of IsdC and EsxA proteins. (A) Structure 
and operon organization of pNM003 for His-IsdC expression and (B) SDS-PAGE of 
purified IsdC (~25.5 kDa). (C) Structure and operon organization of pNM002 for His-
EsxA expression and (D) SDS-PAGE of purified EsxA (~14.5 kDa). E1= elution 1, E2 
= elution 2. 
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Figure 4-6. Antigen-specific IgG responses from S. aureus culture positive and S. 
aureus culture negative bovine milk. (A) anti-IsdA, (B) anti-IsdC, and (C) anti-EsxA 
IgG responses. Data are presented as the log transformed geometric mean of 
independent titers from five cows. Significance (*) of anti-IsdA (p=0.014), anti-IsdC 
(p=0.035) and EsxA (p=0.019) using a two-tailed Student’s t-test for unequal variance. 
Discussion  
Bacterial surface proteins are critical immunodominant antigens that are often the 
first molecules to interact with host cells and tissues. These proteins are especially 
important targets for S. aureus vaccine development as they are also key for adhesion and 
nutrient acquisition, and their presence and structure more conserved across strains than 
the polysaccharide capsule [254]. In this study, our approach was to identify 
immunogenic cell wall associated and surface proteins for characterization as vaccine 
antigens to prevent S. aureus bovine mastitis. The presence of anti-staphylococcal IgG 
antibodies in milk during subclinical and clinical bovine mastitis has been reported [92]. 
Here, we report a unique immunoproteomics strategy to detect antigenic staphylococcal 
proteins using IgG present in milk. A total of 38 unique and immunogenic S. aureus 
proteins were identified, out of which 17 proteins were cell wall associated, or 
extracellular, and previously reported as involved in virulence. Eight proteins were 
further ranked based upon their subcellular location, coverage and function and two of 
them,  IsdC and EsxA, purified for confirmation of immune responses [21]. 
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Despite taking precautions to minimize cell lysis, this approach did also identify 
intracellular or cytosolic proteins including: elongation factors and ribosomal proteins 
(Supplementary Table 1). Adjustment of trypsinization time and conditions did not 
eliminate the presence of these proteins, and the detection of cytosolic proteins is a 
recognized limitation of immunoproteomics [255]. While immunogenic cytosolic 
proteins can be potential vaccine antigens, they may also be detected due to abundance, 
and thus we did not pursue the characterization of them [256]. Phase of growth is also a 
key consideration for immunoproteomics. We targeted the late exponential phase and 
early stationary phases of growth (0.75-1.2 OD600 in LIM) as previous reports, and our 
studies, have indicated this range is optimal for isdA and other virulence factor 
expression [257]. IsdA is a well characterized immunogenic surface adhesin from S. 
aureus, and we, unexpectedly, did not identify this protein using these techniques [258]. 
Lack of identification of IsdA could be due to trypsinization methods that result in 
aberrant IsdA cleavage, lack of release of IsdA due to surface hydrophobicity, or low 
peptide concentration that was not detected or not fully resolved from other spots/proteins 
[259]. We attempted to isolate surface proteins using alternate techniques, including: 
lysostaphin and silica beads (data not shown), but these efforts resulted in the 
identification of many more cytosolic proteins. Trypsinization enables extraction of 
surface proteins effectively but is limited to exposed lysine and arginine amino acid 
residues on the surface. Despite these limitations, a number of immunogenic S. aureus 
virulence factors that may represent bovine vaccine candidates were identified, and 
results emphasize the significance of milk antibodies for the identification of antigens 
exposed during udder colonization and mastitis.  
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Out of the top eight identified proteins, IsdC and EsxA were selected for further 
analysis on the basis of coverage by mass spectrometry, cell wall location and function in 
relation to virulence and pathogenesis. IsdC and EsxA were tested for reactivity to bovine 
milk from S. aureus infected cows as an indicator of surface exposure in vivo. In 
comparison to the IsdA antigen, which has been reported to induce antibody production 
during S. aureus mastitis, EsxA and IsdC were also immunogenic [184]. These proteins 
have been studied and described as virulence factors for S. aureus pathogenesis. EsxA is 
a surface exposed S. aureus protein as determined by trypsinization and mass 
spectrometry [260]. This protein is also an important factor for pathogenesis and abscess 
formation in mice [261]. A recent report identified anti-EsxA antibodies in patients 
infected with antibiotic resistant strains of S. aureus [81]. EsxA has also been evaluated 
as a vaccine candidate, and induces Th1 and Th17 immune responses against invasive S. 
aureus in murine models [82,262]. IsdC is a surface adhesin from the Isd (iron regulated 
surface determinant) family that is required for iron sequestration and ECM binding. IsdC 
is involved in haem transfer from the membrane to the cytosol and important, but not 
essential, for S. aureus iron uptake [263]. IsdC contains one near-iron-transporter 
(NEAT) domain similar to IsdA, and may contribute to biofilm formation through 
dimerization [84]. In this study, we found both IsdC and EsxA to be highly conserved at 
the amino acid level using published genomes, and isdC and esxA were present in 92% of 
tested bovine S. aureus isolates.  
Other proteins identified using this technique also represent interesting vaccine 
candidates, including: FeoB, Map, SpA and IsaA [248,264–268]. These proteins were not 
currently selected for further analysis due to significantly lower coverage by mass 
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spectrometry. However, a number of them have been pursued as human vaccine 
candidates and may also represent bovine candidates. While additional studies are 
required to assess the specific immunogenicity and protective efficacy of IsdC and EsxA 
in bovines, the methods described here are unique and represent a useful screen to 
identify bovine mastitis vaccine candidates. 
 
Table 4-4. S. aureus proteins identified as ranked by mass spectrometry coverage 
 
Accession No. Protein name Symbol Coverage # AAs Function Location Trans-
membrane 
helices 
Q99WU4 ESAT-6 secretion system 
extracellular protein A  
ESXA 89.69 97 Virulence factor Extracellular 0 
Q2FJN4 Alkyl hydroperoxide reductase 
subunit C  
AHPC 40.21 189 Peroxidase activity  Cytoplasm 0 
A7X3V3 UPF0342 protein SAHV_1830 Y1830 32.46 114 unknown Cytoplasm 0 
A6U0U8 Iron-regulated surface 
determinant protein C  
ISDC 29.07 227 Hemoglobin binding/metal 
ion binding 
Cell wall, extra 
cellular 
2 
Q2FEQ7 50S ribosomal protein L30 RL30 23.73 59 Structural constituent of 
ribosome  
Cytoplasm 0 
Q5HG56 Probable tautomerase 
SACOL1399  
Y1399 19.67 61 Isomerase activity  Cytoplasm 0 
P02976 Immunoglobulin G-binding 
protein A  
SPA 18.80 516 IgG binding  Cell wall 1 
P60157 Probable transglucosylase IsaA  ISAA 15.02 233 Hydrolase activity, acting on 
glycosyl bonds  
Extracellular 0 
P99075 Fructose-bisphosphate 
aldolase  
ALF2 9.79 286 Fructose-bisphosphate 
aldolase activity  
Cytoplasm 0 
A6U135 Methionyl-tRNA formyl 
transferase  
FMT 8.68 311 Methionyl-tRNA formyl 
transferase activity  
Cytoplasm 0 
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A6U174 30S ribosomal protein S2 RS2 8.24 255 Structural constituent of 
ribosome  
Cytoplasm 0 
P0AEZ5 Septum site-determining 
protein MinD  
MIND 7.04 270 ATPase activity  Cell membrane 0 
P39851 Putative tyrosine-protein 
kinase CapB  
CAPB 4.82 228 ATP binding  Cytoplasmic 
Membrane 
0 
P66816 NAD-dependent protein 
deacetylase  
NPD 4.53 243 Metal ion binding  Cytoplasm 0 
Q6GI27 Protein FmtA FMTA 4.28 397 Antibiotic resistance Cell membrane  1 
P63582 Arginosuccinate lyase  ARLY 4.14 459 Arginosuccinate lyase 
activity  
Cytoplasm 0 
P35272 Chain length determinant 
protein  
WZZB3 4.00 325 unknown Cell inner 
membrane; 
2 
Q8FB30 tRNA-dihydrouridine DUSA 3.93 331 Flavin adenine dinucleotide 
binding  
Cytoplasm 0 
P37386 Probable cadmium-
transporting ATPase  
CADA2 3.86 804 ATP binding  Cell membrane  7 
Q2YU20 Putative multidrug export ATP-
binding/permease protein 
SAB1799c  
Y1799 3.81 578 ATPase activity, coupled to 
transmembrane movement 
of substances  
Cell membrane  5 
Q2YUG0 tRNA N6-adenosine threonyl 
carbamoyl transferase  
TSAD 3.52 341 metal ion binding  Cytoplasmic 0 
Q6G845 UPF0421 protein SAS1811 Y1811 3.35 328 unknown Cell membrane  4 
Q2FVZ4 Lipid II: glycine 
glycyltransferase  
FEMX 3.33 421 Transferase activity, 
transferring amino-acyl 
groups  
Cytoplasm 0 
P58995 dITP/XTP pyrophosphatase  IXTPA 3.08 195 metal ion binding  Cytoplasm 0 
Q5HD01 Fe (Ferrous iron transport 
protein B) 
FEOB 3.01 664 Ferrous iron 
transmembrane transporter 
activity  
Cell membrane  10 
Q5HE97 ATP synthase subunit beta  ATPB 2.98 470 ATP binding  Cell membrane  0 
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Q2FWE3 Low molecular weight protein-
tyrosine-phosphatase PtpB  
PTPB 2.88 139 Protein tyrosine 
phosphatase activity  
Cytoplasm 0 
P21224 Uncharacterized leukocidin-
like protein 1 
LUKL1 2.66 338 Pathogenesis Extracellular 0 
Q99V41 Bifunctional autolysin 
[Includes: N-acetylmuramyl-L-
alanine amidase  
ATL 2 1248 Amidase activity  Cell wall 0 
Q5HGM7 Orotate phosphoribosyl 
transferase  
PYRE 1.97 203 Orotate phosphoribosyl 
transferase activity  
Cytoplasm 0 
P72367 Capsular polysaccharide type 8 
biosynthesis protein cap8A 
CAP8A 1.80 222 Sugar efflux transmembrane 
transporter activity  
Cell membrane 2 
Q6GDD3 Lipase 1  LIP1 1.62 680 Metal ion binding  Extracellular/ 
membrane  
1 
A6U074 ATP-dependent 
helicase/nuclease subunit A  
ADDA 1.56 1217 ATP binding  Cytoplasm 0 
Q6GBT3 Probable branched-chain-
amino-acid aminotransferase  
ILVE 1.40 358 L-isoleucine transaminase 
activity  
Cytoplasm 0 
Q69HT9 Multicopper oxidase MCO 1.34 447 Copper ion binding  Cytoplasm 0 
Q5HG29 Conserved virulence factor B CVFB 1.33 300 unknown Cell membrane 0 
Q6GGU4 3-dehydroquinate synthase  AROB 1.13 354 3-dehydroquinate synthase 
activity  
Cytoplasm 0 
Q7A695 N5-carboxyaminoimidazole 
ribonucleotide synthase  
PURK 1.07 374 5(carboxyamino)imidazole 
ribonucleotide synthase 
activity  
Cytoplasmic 
Membrane 
0 
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CONCLUSIONS AND INTERPRETATIONS 
The chapters of this work focus on evaluating various aspects of designing a 
mucosal vaccine against S. aureus mastitis. We hypothesized that a mucosal, enterotoxin-
based vaccine containing multiple relevant antigens will protect cows against S. aureus 
mastitis. To being to address this hypothesis and construct a vaccine for bovine mastitis, 
experimentation focused on three main areas: 1) characterizing the IsdA antigen for its 
intra-strain conservation, ECM binding, and immune reactivity for use as a bovine 
vaccine candidate, 2) analyzing the immunogenicity and safety of a cholera toxin based 
subunit vaccine (IsdA-CTA2/B + ClfA-CTA2/B), and 3) developing an 
immunoproteomics approach to discover new proteins from S. aureus that can be 
incorporated into the vaccine. As discussed in Chapter 1, deteriorating animal health and 
economic losses caused by bovine mastitis is a worldwide concern. S. aureus caused 
mastitis is of critical importance due to refractory antibiotic treatments and the growing 
incidence of antibiotic resistance. Additionally, the contagious nature of S. aureus caused 
mastitis and ability to establish subclinical infection make prevention of this disease a top 
priority. An effective vaccine against this pathogen that can prevent mastitis caused by 
different strains and serotypes will reduce the use of antibiotics, improve animal health, 
reduce economic losses and also provide valuable information for human S. aureus 
vaccine development. 
IsdA has been previously described as an important vaccine antigen and is also 
used in potential human vaccines with other antigens. However, the characterization of 
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IsdA specifically as a bovine antigen has not been reported and is explored here for the 
first time. It is known that, due to intra-strain variability, the conservation of antigens is 
critically important for a vaccine against a pathogen like S. aureus. As discussed in 
Chapter 2, a main focus of this research was to identify the genetic prevalence and 
expression of IsdA from bovine S. aureus. Our results indicate that IsdA is present in 28 
strains from a total of 29, making it 97% percent conserved (Table 2-2, Chapter 2). In 
addition to IsdA we also detected prevalence of a number of other surface adhesins from 
S. aureus (Table 2-2, Chapter 2). Immunogenicity assays from this study revealed that the 
IsdA antigen can stimulate antigen-specific active antibodies that were capable of 
opsonophagocytosis, supporting the conclusion that IsdA is a promising bovine vaccine 
antigen. Multiple alignment of the IsdA protein revealed the presence of two different 
variants of IsdA (represented by strains Newbould 305 and MRSA252). Four amino acid 
differences observed at the C-terminal of these two variants of IsdA mediated variable 
binding preferences to the host ECM molecules FN and FG (Figure 2-2, Chapter 2). The 
NEAT domain of IsdA is known to coordinate FG binding, however, the role of the C-
terminal in ECM binding was identified in this study for the first time.  
The studies described in Chapter 2 determined that IsdA is expressed in milk in 
vivo during active S. aureus infection. To detect the level of expression of isdA and other 
antigens in vitro we performed additional qRT-PCR analysis of isdA, clfA, isdB and flbA 
under the iron limiting conditions of milk using S. aureus (Newbould 305), S. aureus 
(MRSA USA300) and S. haemolyticus. These results revealed that there is increased 
expression of isdA, isdB and clfA in the iron limiting conditions of milk from S. aureus 
(305 Newbould) and S. aureus (MRSA), but not S. haemolyticus. Although the 
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expression was increased for all three adhesins, isdA and isdB showed higher expression 
than clfA (Appendix A, Figure A-1). Furthermore, we conducted growth curve analysis 
on all the three strains, to detect if the change in expression in milk is solely due to 
growth phase changes, and the results indicated partial interdependence of expression on 
growth phase as well as iron limitation (Figure A-2, Appendix A). In addition, we 
identified enhanced binding of bovine strains of S. aureus (305, Newbould) to FN in milk 
as compared to LB (Figure A-3, Appendix A).  
The data presented in Chapter 2 and Appendix A highlight that IsdA is an 
important surface adhesin for S. aureus and a promising candidate for bovine vaccines. 
Although IsdA is likely to be highly conserved, future studies with a larger number of 
strains, from different geographical regions, will be important, for better characterization 
of this antigen. Also, additional in vitro gene expression studies in low iron conditions of 
milk with immunogenic proteins (IsdC, EsxA and SpA) will be valuable to understand 
their roles in bovine mastitis. The ECM binding assays of our study, revealed higher 
binding of bovine strains to FN in the presence of milk, however, binding with other 
ECM molecules like laminin and collagen IV should be evaluated, as these molecules are 
also abundant in bovine udder and are involved in mammary gland development. Lastly, 
creating a isdA targeted gene mutant to study the pathogenicity and ECM binding of this 
antigen in vitro and in vivo might be the gold standard, however, redundancy of S. aureus 
adhesins have in the past been shown to be a problem for analysis in mutational studies. 
As discussed in Chapter 3, two field trials on the mucosal subunit vaccine 
containing IsdA and ClfA (IsdA-CTA2/B and ClfA-CTA2/B) were conducted. The trails 
differed in the amount of vaccine administered and the number of booster doses 
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thereafter. Results indicate that the stimulation of significant immune responses occurred 
in vaccinated animals and a slight but effective booster response occurred that produced 
antibody responses prior to freshening. Trial 2 in these studies had a higher dosage of 
vaccine from the start which contributed to higher immune responses throughout the 50-
day vaccination trial period. IsdA and ClfA were able to induce antigen-specific 
antibodies, however, IsdA consistently showed higher and more significant immune 
responses. The vaccine induced significant humoral and cellular immune responses in 
serum, and while significance responses in milk were not detected by ELISA, data 
supportive. Increased expression of IL-4 cytokines was determined on day 60 of Trial 2, 
indicating that this vaccine induces aTh2 bias. Importantly, serum and milk antibodies 
stimulated by the vaccine were able to successfully induce opsonophagocytosis (Figure 
3-3 and 3-4, Chapter 3). These results provide evidence that induced antibodies were 
active and specific to the antigen, which is key for a successful S. aureus vaccine. 
Antibodies stimulated in milk could also significantly induce opsonophagocytosis, 
despite being non- significant in ELISA immune assays, indicating that these important 
antibodies are also present and efficient in inducing bacterial killing (Figure 3-7, Chapter 
3). Overall results from immunogenicity trials show that the vaccine is inducing effective 
immune responses, however the immune stimulation was lower in milk, indicating that 
there is a requirement for more exploration of additional antigens and the mechanisms 
involved. The intranasal route showed promising results, although other methods like 
intramammary or intravaginal routes of delivery might also be explored in the future. A 
challenge trial for this vaccine is underway, and although these studies are technically 
difficult, it might provide valuable information about the protective capabilities of the 
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vaccine. Further, a field trial with a larger number of cows and with newer immunogenic 
antigens will be important to detect the enhancement of the effectiveness of the 
multivalent vaccine. In addition, more knowledge on the critical role of specific antigen 
during mastitis can be evaluated on mastitic mouse models. 
The mucosal vaccine analyzed in Chapter 3, was comprised of two antigens, and 
we aim to incorporate new antigens into this vaccine in the future. To identify new 
immunogenic proteins from the surface of S. aureus, we developed an 
immunoproteomics based approach as described in Chapter 4. This unique approach 
allowed us to detect immunogenic proteins from the surface of S. aureus by using milk 
antibodies (Figures 4-1, 4-2 and 4-3, Chapter 4). Two-dimensional electrophoresis 
coupled with western blotting and mass spectrometry, led to the identification of 54 
proteins from S. aureus and 8 unique immunogenic surface proteins involved in 
virulence. Two of the eight proteins, IsdC and EsxA, showed high immunogenic potential 
and, with further characterization, can be incorporated into the vaccine (Figure 4-6, 
Chapter 4). Further analysis on 6 of the identified 8 surface proteins is underway through 
cloning and protein purification. After this characterization, these antigens can be 
potentially incorporated into the mucosal S. aureus vaccine. Although this technique 
enabled us to discover new antigens, few well-known immunogenic antigens like IsdB, 
ClfA, and FnbpA, were identified in these experiments, which suggests a limitation. This 
technique strongly relies on the capability of trypsin to shave off the surface proteins, 
which means cleaving only on lysine and arginine residues. Thus, important 
immunogenic proteins may have been missed. Future work for this aim may include the 
extraction of surface proteins from S. aureus under more stringent conditions of digestion 
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time, growth phase and concentration of trypsin to ensure less contamination of cytosolic 
proteins, and may also include the use of other enzymes like elastase and proteinase K for 
surface protein extraction by S. aureus. 
The innovation and unique activity of this bovine S. aureus mucosal vaccine lies 
in its purified and multivalent nature, and its combination with a cholera toxin-based 
adjuvant. Cholera toxin adjuvant is a well-known and potent immunomodulator, that aids 
in antigen presentation, B cell isotype switching and translocation of co-administered 
antigens. This adjuvant, in combination with S. aureus surface proteins that are key 
targets for blockage, has the capacity to prevent bacterial colonization. While the 
protective efficacy of this vaccine is yet to be determined, the experiments described are 
essential steps in its progress and development, and these studies suggest it has the 
potential to improve animal health by preventing bovine mastitis caused by S. aureus. An 
effective vaccine would have positive impacts on milk production, antibiotic use, and 
agricultural economics and may also have lasting positive effects on human health and 
nutrition.  
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APPENDIX A 
The Low Iron Conditions of Milk Promote Staphylococcus Aureus IsdA Expression 
and Fibronectin Binding
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Materials and Methods 
Bacterial growth, RNA isolation and quantitative real-time PCR.  
S. aureus Newbould 305, S. aureus USA 300 and S. haemolyticus (bovine, isdA+) 
were grown in Luria Broth (LB) to a bacterial count of 1x 108 cells. Cultures were 
harvested and grown microaerophilically in 5% skim milk (SKM), SKM + 200 M 
FeSO4, LB or Low Iron Media (LIM: 2 g NaCl, 1.2 g NaHCO3, 1.6 g yeast extract, 6 g 
protease peptone to 400 mL) at 37°C (21). Optical density was determined at 600 nm 
every 4 hours. At 12 hr and 24 hr, cultures were centrifuged at 3000 Xg and the pellet 
was washed 2X in buffer (1X PBS + 0.5 mM EDTA). Total RNA was extracted from the 
cell pellet as described above for RT-PCR. RNA was suspended in 30 μl RNase free 
water and then stored at -80°C. RNA concentration and purity was confirmed by the 
260/280 ratio (Nanodrop, Thermo-Fisher) and PCR reactions were conducted between 
each step to ensure the absence of genomic DNA. Total isolated RNA was used to 
synthesize first strand cDNA according to manufacturer’s instructions (Revert Aid Kit, 
Thermo-Fisher). Resulting cDNA was diluted 1:500 with RNase free water prior to qRT-
PCR. The qRT-PCR was conducted using SYBR FAST qPCR master mix (Kappa 
Biosystems, Wilmington, MA). All samples were assayed using standard cycling 
conditions of: denaturation at 95 °C for 3 min and 40 amplification cycles of 95 °C for 15 
sec, 60 °C for 30 sec and 72 °C for 30 sec (Eppendorf Mastercycler Realplex2 ). All 
reactions contained 2 μl of cDNA template, 10 μl of SYBR Green Master Mix (2X), 0.5 
μl of 100 μM of each primer, and 7 μl of RNase free water. Fold changes were calculated 
using ΔΔCT method keeping 16S as normalizer. 16S RNA was the most stable 
housekeeping gene in our experiments. All the experiments were conducted with three 
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biological replicates repeated at least three times. 
Fibronectin binding assays.  
Black walled and clear walled (Nunc, Thermo-Fisher) ninety-six well plates were 
coated with 50 µl of 10 µg/mL fibronectin (R&D Systems, Minneapolis, MN) in 1x PBS, 
and incubated for 12 hr at 4°C, followed by two washes of 100 l in 1X PBS. Plates were 
then incubated at 37°C with 1x108 cells of S. aureus Newbould 305, S. aureus USA300, 
or S. haemolyticus (isdA+) in either LB versus SKM, or SKM versus SKM + 200 M 
FeSO4 for 12 hours. After incubation, the plates were washed with 100 l of 1X PBS two 
times and 150 μl Alamar Blue dye (0.1% reazzurin in 1X PBS) was added to black 
walled plates for the fluorescent metabolic dye assay. Plates were read at 530/590 nm 
after 12, 18 and 24 hrs. Assays were also performed by adding 100 l of top agar (10 g 
LB, 3 g agar to total 400 mL) to clear walled plates instead of Alamar Blue. Bacterial 
growth was quantified by the absorbance of top agar plates read at 600 nm after 12 and 
24 hrs at 37°C. For serum-blocking, assays were performed as described above, however 
1:100 dilution of heat inactivated immunized and mock immunized (1X PBS) mouse 
serum was mixed with 1x108 cells of S. aureus MRSA252 that had been grown overnight 
in LIM. The mixture was incubated at 37°C for 30 mins and 100 L was added to the 
ninety-six well plates containing 10 ug/mL fibronectin in 2-fold dilutions. Plates were 
washed and quantified with Alamar Blue as described. Pooled, day 14 anti-IsdA mouse 
serum was obtained after intranasal vaccination of 6 9-week old BALB/c mice that 
received purified IsdA (17 g) plus CT (5 g) adjuvant on days 0 and 10, as described 
previously (22).  
Graphing and statistical analysis.  
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All graphing and statistical analysis was performed with JMP SAS software 
(Cary, NC) or R version 3863.0.2. PCRs, ELISAs and CFU assays were performed in 
triplicate. The ΔΔCT method was used to calculate fold changes for qPCR experiments. 
Significance was calculated using Tukey-Kramer pairwise comparison on JMP software 
using three biological and two test replicates. Significance between antibody responses, 
SCC and CFU counts were determined using the non-parametric Wilcoxon Rank Score 
(Mann-Whitney) test or between three groups using the Tukey-Kramer pairwise 
comparison. P-values are reported as p < 0.05(*) or p < 0.01(**) with a value of p <0.05 
considered statistically significant. 
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Figure A-1. Expression of staphylococcal adhesins in vitro. Quantitative RT-PCR 
showing normalized Ct values as fold change comparison of gene expression after 
growth of human and bovine Staphylococcus in A) 5% skim milk (SKM) compared 
to Luria broth (LB), B) low iron media (LIM) compared to LB and C) SKM plus 
FeSO4 compared to SKM alone, after 24 hours at 37C. Significance using the Tukey-
Kramer pairwise comparison, p ≤ 0.05(*), p ≤ 0.01(**), p ≤ 0.001 (***) or p ≤ 0.0001 
(****) between the expression of genes is shown. 
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Figure A-2. Growth curves of human and bovine staphylococcal isolates Colony 
forming units (CFU/mL) of A) bovine S. aureus Newbould 305, B) human S. aureus 
USA300 and C) bovine S. haemolyticus grown in vitro for 28 hours in LB (green), 
SKM (red) and LIM (blue).  
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Figure A-3. Binding of human and bovine staphylococcal isolates to fibronectin. 
Fibronectin-binding as determined by metabolic dye assay of S. aureus Newbould 
305, S. aureus USA300 and S. haemolyticus after growth in A) SKM versus LB and 
B) SKM versus SKM +FeSO4. Significance using the Student’s T-test, p ≤ 0.05(*), p 
≤ 0.01(**) or p ≤ 0.001 (***), between fibronectin binding after growth in different 
media is shown. 
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Figure A-4. Quantitative RT-PCR of adhesin expression from bovine S. aureus 
Novel Cow (NC) Normalized Ct values as fold change comparison of gene expression 
are shown after growth of NC in A) 5% skim milk (SKM) compared to Luria broth 
(LB), B) low iron media (LIM) compared to LB and C) SKM plus FeSO4 compared 
to SKM alone, after 24 hours at 37C. D) Growth curve in CFU/mL of NC growth LB 
(green), SKM (red) and LIM (blue). Significance using the Tukey-Kramer pairwise 
comparison, p ≤ 0.05(*), p ≤ 0.01(**), p ≤ 0.001 (***) or p ≤ 0.0001 (****) between 
the expression of genes is shown. 
